

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053141 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: **PCT/US01/48458**

(22) International Filing Date:
14 December 2001 (14.12.2001)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/255,534 14 December 2000 (14.12.2000) **US**

(71) Applicant: **COLEY PHARMACEUTICAL GROUP, INC.** [US/US]; Suite 101, 93 Worcester Street, Wellesley, MA 02481 (US).

(72) Inventor: **BRATZLER, Robert, L.**; 84 Barns Hill Road, Concord, MA 01742 (US).

(74) Agent: **TREVISAN, Maria, A.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS**



(57) Abstract: The invention relates to methods and products for inhibiting angiogenesis. At least one antiangiogenic nucleic acid molecule is administered to a subject to prevent or treat unwanted angiogenesis. Non-nucleic acid antiangiogenic agents also can be administered.

BEST AVAILABLE COPY

WO 02/053141 A2

INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS

Background of the Invention

Blood vessels are the means by which oxygen and nutrients are supplied to living
5 tissues and waste products are removed from living tissue. Angiogenesis refers to the process
by which new blood vessels are formed. See, for example, the review by Folkman and Shing,
J. Biol. Chem. 267(16):10931-10934, 1992. Thus, where appropriate, angiogenesis is a
critical biological process. It is essential in reproduction, development and wound repair.
However, inappropriate angiogenesis can have severe negative consequences. For example, it
10 is only after many solid tumors are vascularized as a result of angiogenesis that the tumors
have a sufficient supply of oxygen and nutrients that permit it to grow rapidly and
metastasize. Because maintaining the rate of angiogenesis in its proper equilibrium is so
critical to a range of functions, it must be carefully regulated in order to maintain health. The
angiogenesis process is believed to begin with the degradation of the basement membrane by
15 proteases secreted from endothelial cells (EC) activated by mitogens such as vascular
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The cells
migrate and proliferate, leading to the formation of solid endothelial cell sprouts into the
stromal space, then, vascular loops are formed and capillary tubes develop with formation of
tight junctions and deposition of new basement membrane.

20 In adults, the proliferation rate of endothelial cells is typically low compared to other
cell types in the body. The turnover time of these cells can exceed one thousand days.
Physiological exceptions in which angiogenesis results in rapid proliferation typically occurs
under tight regulation, such as found in the female reproduction system and during wound
healing.

25 The rate of angiogenesis involves a change in the local equilibrium between positive
and negative regulators of the growth of microvessels. The therapeutic implications of
angiogenic growth factors were first described by Folkman and colleagues over two decades
ago (Folkman, *N. Engl. J. Med.* 285:1182-1186, 1971). Abnormal angiogenesis occurs when
the body loses at least some control of angiogenesis, resulting in either excessive or
30 insufficient blood vessel growth. For instance, conditions such as ulcers, strokes, and heart
attacks may result from the absence of angiogenesis normally required for natural healing. In
contrast, excessive blood vessel proliferation can result in tumor growth, tumor spread,
blindness, psoriasis and rheumatoid arthritis.

- 2 -

There are instances where a greater degree of angiogenesis is desirable, e.g., increasing blood circulation, wound healing, and ulcer healing. For example, recent investigations have established the feasibility of using recombinant angiogenic growth factors, such as fibroblast growth factor (FGF) family (Yanagisawa-Miwa et al., *Science*, 257:1401-1403, 1992; Baffour et al., *J. Vasc. Surg.* 16:181-91, 1992), endothelial cell growth factor (ECGF; Pu et al., *J. Surg. Res.* 54:575-83, 1993), and more recently, vascular endothelial growth factor (VEGF) to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia (Takeshita et al., *Circulation*, 90:228-234, 1994; Takeshita et al., *J. Clin. Invest.* 93:662-70, 1994).

Conversely, there are instances where inhibition of angiogenesis is desirable. For example, many diseases are driven by persistent unregulated angiogenesis, also sometimes referred to as "neovascularization". In arthritis, new capillary blood vessels invade the joint and destroy cartilage. In diabetes, new capillaries invade the vitreous of the eye, bleed, and cause blindness. Ocular neovascularization is the most common cause of blindness. Tumor growth and metastasis are angiogenesis-dependent. A tumor must continuously stimulate the growth of new capillary blood vessels for the tumor itself to grow.

The current approved treatment of these diseases is inadequate. Agents which prevent continued angiogenesis, such as drugs (e.g. TNP-470), monoclonal antibodies, antisense nucleic acids and proteins (e.g., angiostatin and endostatin) are currently being tested, but have not been approved. Although preliminary results with the antiangiogenic proteins are promising, they are relatively large in size and are difficult to use and produce. Moreover, proteins are subject to enzymatic degradation. Thus, new agents that inhibit angiogenesis are needed. New antiangiogenic agents that show improvement in size, ease of production, stability and/or potency would be desirable.

Summary of the Invention

It has now been discovered that nucleic acid molecules, including oligonucleotides, have intrinsic antiangiogenesis properties apart from the proteins such nucleic acids may encode.

According to one aspect of the invention, methods for inhibiting angiogenesis are provided. The methods include administering to a subject in need of such treatment at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis in the subject. In some embodiments, two or more antiangiogenic nucleic acid molecules are

- 3 -

administered. In other embodiments, non-nucleic acid antiangiogenic agents also are administered and agents that are effective against other aspects of an angiogenic condition (e.g., anticancer agents) can also be administered. In some embodiments, the angiogenesis is associated with a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation. In other embodiments, the angiogenesis is not associated with a cancer or tumor, but may be associated with an eye or ocular disorder such as those described herein. In still other embodiments, the angiogenesis is associated with embryo implantation. In certain embodiments, the angiogenesis is associated with conditions involving excessive or abnormal stimulation of endothelial cells such as but not limited to intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.

In other aspects of the invention, compositions are provided that include at least one antiangiogenic nucleic acid molecule, formulated in a pharmaceutically-acceptable carrier and in an effective amount for inhibiting angiogenesis. The compositions in certain embodiments include non-nucleic acid antiangiogenic agents and/or agents that are effective against other aspects of an angiogenic condition (e.g., anticancer agents).

According to still other aspects the invention, kits are provided that include a first container housing at least one antiangiogenic nucleic acid molecule and instructions for administering the antiangiogenic nucleic acid molecule to a subject having unwanted angiogenesis. In certain embodiments, a second container housing at least one non-nucleic acid antiangiogenic agent is also provided. In other embodiments of the foregoing kits, another container housing at least one anticancer agent is provided. In certain embodiments, the instructions relate to administering the antiangiogenic nucleic acid to a subject having a condition that is not cancer or a tumor, and examples of such conditions are listed throughout the specification.

A nucleic acid molecule is an element of each aspect of the invention. Preferred nucleic acid molecules include at least one sequence set forth as SEQ ID NOS: 1-1093. The nucleic acids useful according to the invention are synthetic or natural (isolated) nucleic acids. The nucleic acid may be administered alone or in conjunction with a pharmaceutically-acceptable carrier and optionally other therapeutic agents. In some embodiments the nucleic

- 4 -

acid is a CpG nucleic acid, including those having an unmethylated CpG motif, a T-rich nucleic acid, or a poly G nucleic acid.

The nucleic acid in some embodiments has a nucleotide backbone which includes at least one backbone modification, such as a phosphorothioate modification or other phosphate modification. In some embodiments the modified backbone is a peptide modified oligonucleotide backbone. The nucleotide backbone may be chimeric, or the nucleotide backbone is entirely modified.

The nucleic acid can have any length greater than 6 nucleotides, but in some embodiments is between 8 and 100 nucleotide residues in length. In other embodiments the nucleic acid comprises at least 20 nucleotides, at least 24 nucleotides, at least 27, nucleotides, or at least 30 nucleotides. The nucleic acid may be single stranded or double stranded. In some embodiments the nucleic acid is isolated and in other embodiments the nucleic acid may be a synthetic nucleic acid. The antiangiogenic nucleic acids in some instances are not antisense molecules.

The CpG nucleic acid in one embodiment contains at least one unmethylated CpG dinucleotide having a sequence including at least the following formula: 5' X₁ X₂CGX₃ X₄ 3' wherein C is unmethylated, wherein X₁, X₂, X₃, and X₄ are nucleotides. In one embodiment the 5' X₁ X₂CGX₃ X₄ 3' sequence of the CpG nucleic acid is a non-palindromic sequence, and in other embodiments it is a palindromic sequence.

In some embodiments X₁X₂ are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X₃X₄ are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. In other embodiments X₁X₂ are GpA or GpT and X₃X₄ are TpT. In yet other embodiments X₁ or X₂ or both are purines and X₃ or X₄ or both are pyrimidines or X₁X₂ are GpA and X₃ or X₄ or both are pyrimidines. In one embodiment X₂ is a T and X₃ is a pyrimidine.

In other embodiments the CpG nucleic acid has a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447,

448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 790-792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In some embodiments the T rich nucleic acid is a poly T nucleic acid comprising 5' TTTT 3'. In yet other embodiments the poly T nucleic acid comprises 5' X₁ X₂ TTTT X₃ X₄ 3' wherein X₁, X₂, X₃ and X₄ are nucleotides. In some embodiments X₁X₂ is TT and/or X₃X₄ is TT. In other embodiments X₁X₂ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and/or X₃X₄ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

The T rich nucleic acid may have only a single poly T motif or it may have a plurality of poly T nucleic acid motifs. In some embodiments the T rich nucleic acid comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 T motifs. In other embodiments it comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 CpG motifs. In some embodiments the plurality of CpG motifs and poly T motifs are interspersed.

In yet other embodiments at least one of the plurality of poly T motifs comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 contiguous T nucleotide residues. In other embodiments the plurality of poly T motifs is at least 3 motifs and wherein at least 3 motifs each comprises at least 3 contiguous T nucleotide residues or the plurality of poly T motifs is at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

The T rich nucleic acid may include one or more CpG motifs. The motifs may be methylated or unmethylated. In other embodiments the T rich nucleic acid is free of one or more CpG dinucleotides.

In other embodiments the T rich nucleic acid has poly A, poly G, and/or poly C motifs. In other embodiments the T rich nucleic acid is free of two poly C sequences of at least 3 contiguous C nucleotide residues. Preferably the T rich nucleic acid is free of two poly A sequences of at least 3 contiguous A nucleotide residues. In other embodiments the T rich nucleic acid comprises a nucleotide composition of greater than 25% C or greater than 25%

- 6 -

A. In yet other embodiments the T rich nucleic acid is free of poly-C sequences, poly G sequences or poly-A sequences.

In some cases the T rich nucleic acid may be free of poly T motifs, but rather, comprises a nucleotide composition of greater than 25% T. In other embodiments the T rich nucleic acid may have poly T motifs and also comprise a nucleotide composition of greater than 25% T. In some embodiments the T rich nucleic acid comprises a nucleotide composition of greater than 25% T, greater than 30% T, greater than 40% T, greater than 50% T, greater than 60% T, greater than 80% T, or greater than 90% T nucleotide residues. . The T rich nucleic acid in some embodiments is selected from the group consisting of SEQ ID NOs: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T rich nucleic acids are sequence selected from the group consisting of SEQ ID NOs: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In some embodiments the poly G nucleic acid comprises: 5' X₁X₂GGGX₃X₄ 3' wherein X₁, X₂, X₃, and X₄ are nucleotides. In embodiments at least one of X₃ and X₄ are a G or both of X₃ and X₄ are a G. In other embodiments the poly G nucleic acid comprises the following formula: 5' GGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In yet other embodiments the poly G nucleic acid comprises the following formula: 5' GGGNGGGNGGG 3' wherein N represents between 0 and 20 nucleotides. The poly G nucleic acid in some embodiments is selected from the group consisting of SEQ ID NOs. : 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes a sequence selected from the group consisting of SEQ ID NOs; 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

The poly G nucleic acid may include one or more CpG motifs or T-rich motifs. The CpG motifs may be methylated or unmethylated. In other embodiments the poly G nucleic acid is free of one or more CpG dinucleotides or poly-T motifs.

- 7 -

The nucleic acid molecules and optionally other agents may be administered by any route known in the art for delivering medicaments. The medicaments may be administered separately or together, in the same pharmaceutical formulation or separate formulations, by the same route or by different routes. In one embodiment the nucleic acid molecule(s) is administered on a routine schedule. In another embodiment the other agent(s) (e.g., antiangiogenesis agents, anticancer agents) is administered on a routine schedule.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

Brief Description of the Drawings

Figure 1 is a histogram showing the effect of a CpG nucleic acid on angiogenesis as measured by hemoglobin content.

The drawing is not required for enablement of the claimed invention.

Detailed Description of the Invention

The present invention includes compositions that include antiangiogenic nucleic acids and methods of using the antiangiogenic nucleic acids for the treatment of diseases that are mediated by angiogenesis. The invention includes antiangiogenic nucleic acids having various nucleotide sequences. The present invention comprises a method of treating undesired angiogenesis in a human or animal comprising the steps of the administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of, for example, an antiangiogenic nucleic acid.

As used herein, the term "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The term "endothelium" means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels. The term "endothelial inhibiting activity" means the capability of a molecule to inhibit angiogenesis in general and, for example, to inhibit the growth of bovine capillary endothelial cells in culture in the presence of fibroblast growth factor.

- 8 -

Antiangiogenic nucleic acids are effective in treating diseases or processes that are mediated by, or involve, angiogenesis. The present invention includes the method of treating an angiogenesis mediated disease with an effective amount of antiangiogenic nucleic acids. The angiogenesis mediated diseases include, but are not limited to, solid tumors; blood born tumors such as leukemias; tumor metastasis; benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; pre-malignant tumors; rheumatoid arthritis; psoriasis; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation.

Antiangiogenic nucleic acids may be useful in the treatment of disease of excessive or abnormal stimulation of endothelial cells. These diseases include, but are not limited to, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars, i.e., keloids.

Antiangiogenic nucleic acid can be used as a birth control agent by preventing vascularization required for embryo implantation.

Antiangiogenic nucleic acids may be useful in the treatment of conditions characterized by abnormal epithelial cell proliferation, such as proliferative dermatologic disorders. These include conditions such as keloids, seborrheic keratosis, papilloma virus infection (e.g. producing verruca vulbaris, verruca plantaris, verruca plana, condylomata, etc.) and eczema.

Antiangiogenic nucleic acids may be useful in the treatment of precancerous lesions such as epithelial precancerous lesions. An epithelial precancerous lesion is a lesion of epithelial cell origin that has a propensity to develop into a cancerous condition. An example is a precancerous skin lesion. Epithelial precancerous skin lesions also arise from other proliferative skin disorders such as hemangiomas, keloids, eczema and papilloma virus infections producing verruca vulbaris, verruca plantaris and verruca planar. The symptoms of the epithelial precancerous lesions include skin-colored or red-brown macule or papule with dry adherent scales. Actinic keratosis is the most common epithelial precancerous lesion among fair skinned individuals. It is usually present as lesions on the skin which may or may not be visually detectable. The size and shape of the lesions varies. It is a photosensitive disorder and may be aggravated by exposure to sunlight. Bowenoid actinic keratosis is another form of an epithelial precancerous lesion. In some cases, the lesions may develop

- 9 -

into an invasive form of squamous cell carcinoma and may pose a significant threat of metastasis. Other types of epithelial precancerous lesions include hypertrophic actinic keratosis, arsenical keratosis, hydrocarbon keratosis, thermal keratosis, radiation keratosis, viral keratosis, Bowen's disease, erythroplakia of queyrat, oral erythroplakia, leukoplakia, and intraepidermal epithelialoma.

Antiangiogenic nucleic acids may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with surgery, radiation or chemotherapy combined with antiangiogenic nucleic acids and then antiangiogenic nucleic acids may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize any residual primary tumor. In some instances it may be preferable to administer the antiangiogenic nucleic acids specifically to a site likely to harbor a metastatic lesion (that may or may not be clinically discernible at the time). A sustained release formulation implanted specifically at the site (or the tissue) where the metastatic lesion is likely to be would be suitable in these latter instances.

In some embodiments, the antiangiogenic nucleic acids of the invention do not interfere with specific receptor-ligand interactions at the cell surface of a cell, thereby causing the stimulation or inhibition of signaling through such receptors. These interactions include those involving heparin binding receptor, VEGF receptor, or EGF receptor.

In still other embodiments, the antiangiogenic nucleic acids are not antisense nucleic acids, meaning that they do not function by binding to complementary genomic DNA or RNA species within a cell and thereby inhibiting the function of said genomic DNA or RNA species. In important embodiments, the antiangiogenesis nucleic acid does not comprise a nucleic acid sequence that corresponds to a VEGF encoding sequence (or is complementary to a VEGF encoding sequence).

The effective dosage for inhibition of angiogenesis *in vivo*, which can be defined as inhibition of capillary endothelial cell proliferation and/or migration and/or blood vessel ingrowth, can be extrapolated from *in vitro* inhibition assays. *In vitro* assays have been developed to screen for inhibition of angiogenesis. Events that can be tested to assess angiogenesis inhibitors include proteolytic degradation of extracellular matrix and/or basement membrane, proliferation of endothelial cells, migration of endothelial cells, and capillary tube formation. The chick chorioallantoic membrane assay (CAM), described by Taylor and Folkman (*Nature* 297:307-312, 1982), can be used to determine whether the compound is capable of inhibiting neovascularization *in vivo*.

- 10 -

In some embodiments, the antiangiogenic nucleic acids are administered in doses, routes and schedules (and also in therapeutic cocktails) that would not result in the stimulation of an immune response.

The effective dosage is dependent not only on the sequence of the nucleic acid molecules used for inhibition of angiogenesis, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor preferably is delivered in a topical or ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor preferably is delivered by means of a biodegradable, polymeric implant.

An "antiangiogenic nucleic acid" as used herein is any nucleic acid containing an antiangiogenic motif or backbone that inhibits capillary endothelial cell proliferation and/or migration and/or blood vessel ingrowth.

The compounds useful according to the invention are nucleic acids. The nucleic acids may be double-stranded or single-stranded. Generally, double-stranded molecules may be more stable *in vivo*, while single-stranded molecules may have increased activity. The terms "nucleic acid" and "oligonucleotide" refer to multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)) or a modified base. As used herein, the terms refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e. a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules as used herein include vectors, e.g., plasmids, as well as oligonucleotides.

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with a covalently modified base and/or sugar. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments the nucleic acids are homogeneous in backbone composition.

- 11 -

The substituted purines and pyrimidines of the nucleic acids include standard purines and pyrimidines such as cytosine as well as base analogs such as C-5 propyne substituted bases (Wagner et al., *Nature Biotechnology* 14:840- 844, 1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

The nucleic acid is a linked polymer of bases or nucleotides. As used herein with respect to linked units of a nucleic acid, "linked" or "linkage" means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the individual units of a nucleic acid, are most common. The individual units of a nucleic acid may be linked, however, by synthetic or modified linkages.

Whenever a nucleic acid is represented by a sequence of letters it will be understood that the nucleotides are in 5'→ 3' order from left to right and that "A" denotes adenosine, "C" denotes cytosine, "G" denotes guanosine, "T" denotes thymidine, and "U" denotes uracil unless otherwise noted.

Nucleic acid molecules useful according to the invention can be obtained from natural nucleic acid sources (e.g. genomic nuclear or mitochondrial DNA or cDNA), or are synthetic (e.g. produced by oligonucleotide synthesis). Nucleic acids isolated from existing nucleic acid sources are referred to herein as native, natural, or isolated nucleic acids. The nucleic acids useful according to the invention may be isolated from any source, including eukaryotic sources, prokaryotic sources, nuclear DNA, mitochondrial DNA, etc. Thus, the term nucleic acid encompasses both synthetic and isolated nucleic acids.

The term "isolated" as used herein refers to a nucleic acid which is substantially free of or which is separated from components which it is normally associated with in nature e.g., nucleic acids, proteins, lipids, carbohydrates or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the nucleic acids are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations. Because an isolated nucleic acid of the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation, the nucleic acid may comprise only a small percentage by weight of the

- 12 -

preparation. The nucleic acid is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems. The nucleic acids can be produced on a large scale in plasmids, (see Sambrook, T., *et al.*, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. After being administered to a subject the plasmid can be degraded into oligonucleotides. One skilled in the art can purify viral, bacterial, eukaryotic, etc. nucleic acids using standard techniques, such as those employing restriction enzymes, exonucleases or endonucleases.

For use in the instant invention, the nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054, 1986; Froehler *et al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986, ; Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986, Gaffney *et al.*, *Tet. Let.* 29:2619-2622, 1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

In some embodiments, the nucleic acids useful according to the invention may function as immunostimulatory nucleic acids. An immunostimulatory nucleic acid is any nucleic acid, as described herein, which is capable of modulating an immune response. A nucleic acid which modulates an immune response is one which produces any form of immune stimulation, including, but not limited to, induction of a cytokine, B cell activation, T cell activation, monocyte activation. Immunostimulatory nucleic acids include, but are not limited to, CpG nucleic acids, T-rich nucleic acids, poly G nucleic acids, and nucleic acids having phosphate modified backbones, such as phosphorothioate backbones.

A "CpG nucleic acid" or a "CpG antiangiogenic nucleic acid" as used herein is a nucleic acid containing at least one unmethylated CpG dinucleotide (cytosine-guanine dinucleotide sequence, i.e. "CpG DNA" or DNA containing a 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and inhibits angiogenesis. The entire CpG nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5' CG 3' must be unmethylated.

In one embodiment the invention provides a CpG nucleic acid represented by at least the formula:



- 13 -


wherein X_1 and X_2 are nucleotides and N is any nucleotide and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N 's each. In some embodiments X_1 is adenine, guanine, or thymine and/or X_2 is cytosine, adenine, or thymine. In other embodiments X_1 is cytosine and/or X_2 is guanine.

5 In other embodiments the CpG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA; N is any nucleotide and N_1 and N_2 are nucleic acid sequences composed of from about 0-25 N 's each. In some
10 embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are GpA and X_3 or X_4 or both are pyrimidines.

15 In another embodiment the CpG nucleic acid has the sequence



Examples of CpG nucleic acids according to the invention include but are not limited to those listed in Table 1, such as SEQ ID NOs: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-
20 141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-
25 485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885,
30 888-904, and 909-913.

A "T rich nucleic acid" or "T rich antiangiogenic nucleic acid" is a nucleic acid which includes at least one poly T sequence and/or which has a nucleotide composition of greater than 25% T nucleotide residues and which inhibits angiogenesis. A nucleic acid having a

- 14 -

poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. Preferably the T rich nucleic acid includes more than one poly T sequence. In preferred embodiments the T rich nucleic acid may have 2, 3, 4, etc poly T sequences, such as SEQ ID NO:246 or SEQ ID NO:433. Other T rich nucleic acids have a nucleotide composition of greater than 25% T nucleotide residues, but do not necessarily include a poly T sequence. In these T rich nucleic acids the T nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, C, and A. In some embodiments the T rich nucleic acids have a nucleotide composition of greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 99%, T nucleotide residues and every integer % in between. Preferably the T rich nucleic acids have at least one poly T sequence and a nucleotide composition of greater than 25% T nucleotide residues.

In one embodiment the T rich nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In one embodiment X_1X_2 is TT and/or X_3X_4 is TT. In another embodiment X_1X_2 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and X_3X_4 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

In some embodiments it is preferred that the T-rich nucleic acid does not contain poly C (CCCC), poly A (AAAA), poly G (GGGG), CpG motifs, or multiple GGs. In other embodiments the T-rich nucleic acid includes these motifs. Thus in some embodiments of the invention the T rich nucleic acids include CpG dinucleotides and in other embodiments the T rich nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or unmethylated.

Examples of T rich nucleic acids that are free of CpG nucleic acids include but are not limited to those listed in Table 1, such as SEQ ID Nos: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913.

Examples of T rich nucleic acids that include CpG nucleic acids include but are not limited to those listed in Table 1, such as SEQ ID Nos: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

- 15 -

Poly G containing nucleic acids are also useful in accordance with the invention. A "poly G nucleic acid" or "poly G antiangiogenic nucleic acid" is a nucleic acid which includes at least one poly G sequence and/or which has a nucleotide composition of greater than 25% G nucleotide residues and which inhibits angiogenesis. A variety of references, including
5 Pisetsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Macaya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.* 116, 991-994 describe the properties of poly G nucleic acids.

10 Poly G nucleic acids preferably are nucleic acids having the following formulas:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In preferred embodiments at least one of X_3 and X_4 are a G. In other embodiments both of X_3 and X_4 are a G. In yet other embodiments the preferred formula is 5' GGGNNGGG 3', or 5' GGGNNGGGNNGGG 3' wherein N represents
15 between 0 and 20 nucleotides. In other embodiments the Poly G nucleic acid is free of unmethylated CG dinucleotides, such as, for example, the nucleic acids listed below as SEQ ID Nos: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes at least one unmethylated CG dinucleotide, such as, for example,
20 the nucleic acids listed above as SEQ ID Nos; 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

The antiangiogenic nucleic acids of the invention can also be those which do not possess CpG, poly-G, or T-rich motifs.

25 Nucleic acids having modified backbones, such as phosphorothioate backbones, also fall within the class of immunostimulatory nucleic acids. U.S. Patents Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a
30 non-sequence specific manner.

The antiangiogenic nucleic acid molecules may be any size of at least 6 nucleotides but in some embodiments are in the range of between 6 and 100 or in some embodiments between 8 and 35 nucleotides in size. Nucleic acids can be produced on a large scale in

- 16 -

plasmids. These may be administered in plasmid form or alternatively they can be degraded into oligonucleotides before administration.

“Palindromic sequence” shall mean an inverted repeat (i.e. a sequence such as ABCDEE'D'C'B'A' in which A and A' are bases capable of forming the usual Watson-Crick base pairs and which includes at least 6 nucleotides in the palindrome. *In vivo*, such sequences may form double-stranded structures. In one embodiment the nucleic acid contains a palindromic sequence. In some embodiments when the nucleic acid is a CpG nucleic acid, a palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome, and optionally is the center of the palindrome. In another embodiment the nucleic acid is free of a palindrome. A nucleic acid that is free of a palindrome does not have any regions of 6 nucleotides or greater in length which are palindromic. A nucleic acid that is free of a palindrome can include a region of less than 6 nucleotides which are palindromic.

A “stabilized nucleic acid molecule” shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of an oligonucleotide has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the oligonucleotide becomes stabilized and therefore exhibits more activity.

Some stabilized oligonucleotides of the instant invention have a modified backbone. It has been demonstrated that modification of the oligonucleotide backbone provides enhanced activity of the nucleic acids when administered *in vivo*. Nucleic acids, including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases. Other modified oligonucleotides include phosphodiester modified oligonucleotide, combinations of phosphodiester and phosphorothioate oligonucleotide, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail in PCT Published Patent Applications claiming priority to U.S. Patent Nos. 6,207,646B1 and 6,239,116B1, the entire contents of which are hereby incorporated by reference. It is believed that these modified oligonucleotides may show more antiangiogenic activity due to enhanced

- 17 -

nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.

Other stabilized oligonucleotides include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Oligonucleotides which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

For use *in vivo*, nucleic acids are preferably relatively resistant to degradation (*e.g.*, via endo- and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. One type of stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, *e.g.*, as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., *Chem. Rev.* 90:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Other sources of nucleic acids useful according to the invention include standard viral and bacterial vectors, many of which are commercially available. In its broadest sense, a "vector" is any nucleic acid material which is ordinarily used to deliver and facilitate the transfer of nucleic acids to cells. The vector as used herein may be an empty vector or a vector carrying a gene which can be expressed. In the case when the vector is carrying a gene the vector generally transports the gene to the target cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In this case the vector optionally includes gene expression sequences to enhance expression of the gene in target cells such as immune cells, but it is not required that the gene be expressed in the cell.

In general, vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources. Viral vectors are one type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary

- 18 -

tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known to the art. Some viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with a nucleic acid to be delivered.

Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA.

Standard protocols for producing empty vectors or vectors carrying genes (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and/or infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. Some plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pcDNA3.1, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

Exemplary antiangiogenic nucleic acid sequences include but are not limited to those antiangiogenic sequences shown in Table 1 (SEQ ID NO: 1 to SEQ ID NO:1093). The Table lists the SEQ ID NO, nucleotide sequence of the oligonucleotide (ODN sequence), and backbone modification, if any.

Backbone modifications are abbreviated as follows:

S = phosphorothioate

O = phosphodiester

SOS = phosphorothioate and phosphodiester chimeric with phosphodiester in middle

- 19 -

SO = phosphorothioate and phosphodiester chimeric with phosphodiester on 3' end

OS = phosphorothioate and phosphodiester chimeric with phosphodiester on 5' end

S2 = phosphorodithioate

S2O = phosphorodithioate and phosphodiester chimeric with phosphodiester on 3' end

5 OS2 = phosphorodithioate and phosphodiester chimeric with phosphodiester on 5' end

X = unknown

p-ethoxy = p-ethoxy backbone; see, e.g., US patent 6,015,886

PO = phosphodiester

ODN sequence symbols, other than a, c, g and t, are as follows:

10 i = inosine

n = a, c, g, or t

d = a, g or t

h = a, c or t

b = c, g or t; if "b" is single and is listed on 5' or 3' end of oligonucleotide, then "b"

15 indicates a biotin moiety attached to that end of the oligonucleotide

q = 5-methyl-cytosine

m = a or c

s = c or g

x = if "x" is single and is listed on 5' or 3' end of oligonucleotide, then "x" indicates a

20 biotin moiety attached to that end of the oligonucleotide

z = 5-methyl-cytidine

f = FITC moiety attached to 5' or 3' end of oligonucleotide

Table 1

SEQ ID NO:	ODN SEQUENCE	BACKBONE
1	tctcccagcgtgcgccat	S
2	ataatccagcttgaaccaag	S
3	ataatcgacgttcaagcaag	S
4	taccgcgtgcgaccctct	S
5	ggggaggggt	S
6	ggggagggg	S
7	ggtgaggtg	S
8	tccatgtzgttcctgatgct	o
9	gctaccttagzgtga	o
10	tccatgazgttcctgatgct	o
11	tccatgacgttcztgatgct	o
12	gctagazgttagtgt	o
13	agctccatggtgctcactg	s
14	ccacgtcgaccctcaggcga	s
15	gcacatcgccccgcagccga	s
16	gtcactcgtggtacctcga	s

- 20 -

17	gttggatacaggccagactttgttg	o
18	gattcaacttgcgctcatcttaggc	o
19	accatggacgaactgtttcccctc	s
20	accatggacgagctgtttcccctc	s
21	accatggacgacctgtttcccctc	s
22	accatggacgtactgtttcccctc	s
23	accatggacggtctgtttcccctc	s
24	accatggacgttctgtttcccctc	s
25	ccactcacatctgctgctccacaag	o
26	acttctcatagtccctttggccag	o
27	tccatgagcttctgagctct	o
28	gaggaaggigiggaigacgt	o
29	gtgaaticgttcicgggict	o
30	aaaaaa	s
31	ccccc	s
32	ctgtca	s
33	tcgtag	s
34	tcgtgg	s
35	cgtcgt	s
36	tccatgtcggtcctgagctct	sos
37	tccatgccggtcctgagctct	sos
38	tccatgacggtcctgagctct	sos
39	tccatgacggtcctgagctct	sos
40	tccatgtcgatcctgagctct	sos
41	tccatgtcgctcctgagctct	sos
42	tccatgtcgttctgagctct	sos
43	tccatgacgttctgagctct	sos
44	tccataacgttctgagctct	sos
45	tccatgacgtcctgagctct	sos
46	tccatcacgtgcctgagctct	sos
47	tccatgctggtcctgagctct	sos
48	tccatgtzggctcctgagctct	sos
49	ccgcttctccagatgagctcatgggtttctccaccaag	o
50	cttgggtggagaaaccatgagctcatctggaggaagcgg	o
51	ccccaaagggatgagaagtt	o
52	agatagcaaatcggtgacg	o
53	ggttcacgtgctcatggctg	o
54	tctcccagcgtgcgccat	s
55	tctcccagcgtgcgccat	s
56	taccgctgcgacctct	s
57	ataatccagcttgaaccaag	s
58	ataatcgacgttcaagcaag	s
59	tccatgattttctgatttt	o
60	ttgtttttttgtttttttgttttt	s
61	ttttttttgtttttttgttttt	o
62	tgtgtttttgtgtttttgtgttt	s
63	tgtgtttgtgtttttgtgttt	o
64	gcattcatcaggcgggcaagaat	o
65	taccgagcttcgacgagatttca	o
66	gcatgacgttgagct	s
67	cacgttgaggggcat	s
68	ctgctgagactggag	s
69	tccatgacgttctgacgtt	s
70	gcatgagcttgagctga	o
71	tcagcgtgcgcc	s
72	atgacgttctgacgtt	s
73	ttttgggggttttgggggtttt	s

- 21 -

74	tctaggccttttttaggcttcc	S
75	tgcatttttttaggccaccat	S
76	tctcccagcgtgcgtgcgccat	s
77	tctcccagcgggcgcat	s
78	tctcccagcgagcgccat	s
79	tctcccagcgcgccat	s
80	ggggtgacgttcagggggg	sos
81	ggggtccagcgtgcgccatggggg	sos
82	ggggtgctcgttcagggggg	sos
83	tccatgctcgttcctgctgtt	s
84	tccatagcgttcctagcgtt	s
85	tcgtcgtgtctccgcttctt	s
86	gcatgacgttgagct	Sos
87	tctcccagcgtgcgccatat	Sos
88	tccatgazgttcctgazgtt	S
89	gcatgazgttgagct	O
90	tccagcgtgcgccata	sos
91	tctcccagcgtgcgccat	O
92	tccatgagcttcctgagctt	O
93	gcatgtcgttgagct	sos
94	tctgacgttcctgacgtt	s
95	gcatgatgttgagct	o
96	gcatttcgaggagct	o
97	gcatgtagctgagct	o
98	tccaggacgttcctagttct	o
99	tccaggagcttcctagttct	o
100	tccaggatgttcctagttct	o
101	tccagtcctagcctagttct	o
102	tccagttcagcctagttct	o
103	gcatggcgttgagct	sos
104	gcatagcgttgagct	sos
105	gcattgcgttgagct	sos
106	gcttgctgttgcttt	sos
107	tctcccagcgttgcgccatat	sos
108	tctcccagcgtgcgttatat	sos
109	tctccctgcgtgcgccatat	sos
110	tctgcgtgcgtgcgccatat	sos
111	tctcctagcgtgcgccatat	sos
112	tctcccagcgtgcgcctttt	sos
113	gctandcghhagc	o
114	tcctgacgttccc	o
115	ggaagacgttaga	o
116	tcctgacgttaga	o
117	tcagaccagctggcgggtgttcctga	o
118	tcaggaacacccgaccagctggctctga	o
119	gctagtcgatagc	o
120	gctagtcgctagc	o
121	gcttgacgtctagc	o
122	gcttgacgttttagc	o
123	gcttgacgtcaagc	o
124	gctagacgttttagc	o
125	tccatgacattcctgatgct	o
126	gctagacgtctagc	o
127	ggctatgtcgttcctagcc	o
128	ggctatgtcgatcctagcc	o
129	ctcatgggttttctccaccaag	o
130	cttggtggagaaacccatgag	o

131	tccatgacgttcctagttct	o
132	ccgcttcctccagatgagctcatg	o
133	catgagctcatctggaggaagcgg	o
134	ccagatgagctcatgggtttctcc	o
135	ggagaaacccatgagctcatctgg	o
136	agcatcaggaacgacatgga	o
137	tccatgacgttcctgacgtt	RNA
138	gcgcgcgcgcgcgcgcgcgcg	o
139	ccggccggccggccggccgg	o
140	ttccaatcagccccaccgctctggccccaccctcaccctcca	o
141	tggagggtgagggtggggccagagcgggtggggctgattggaa	o
142	tcaaattgtgggattttcccatgagctct	o
143	agactcatgggaaaatcccacatttga	o
144	tgccaagtgcctgagtcactaataaaga	o
145	tctttattagtgactcagcacttggca	o
146	tgcaggaagtccgggttttccccaaccccc	o
147	ggggggttgggggaaaaccggacttctctgca	o
148	ggggactttccgctggggactttccagggggactttcc	Sos
149	tccatgacgttcctctccatgacgttcctctccatgacgttcctc	o
150	gaggaacgtcatggagaggaacgtcatggagaggaacgtcatgga	o
151	ataatagagcttcaagcaag	s
152	tccatgacgttcctgacgtt	s
153	tccatgacgttcctgacgtt	sos
154	tccaggactttctcagggtt	s
155	tcttgcatgctaaaggacgtcacattgcacaattttaataaggt	o
156	accttattaagattgtgcaatgtgacgtccttttagcatcgcaaga	o
157	tctgacgttcctggcgggtcctgtcgct	o
158	tctgtcgctcctgtcgct	o
159	tctgacgttgaagt	o
160	tctgtcggttgaagt	o
161	tctggcggttgaagt	o
162	tctgccggttgaagt	o
163	tcttacgttgaagt	o
164	tctaacgttgaagt	o
165	tctcacgttgaagt	o
166	tctgacgatgaagt	o
167	tctgacgctgaagt	o
168	tctgacggtgaagt	o
169	tctgacgtagaagt	o
170	tctgacgtcgaagt	o
171	tctgacgtggaagt	o
172	tctgagcttgaagt	o
173	gggggacgttggggg	o
174	tctgacgttccttc	o
175	tctcccagcgagcgagcgccat	s
176	tctgacgttcccctggcgggtcccctgtcgct	o
177	tctgtcgctcctgtcgctcctgtcgct	o
178	tctggcggggaagt	o
179	tctgazgttgaagt	o
180	tcztgacgttgaagt	o
181	tcttagcgttgaagt	o
182	tccagacgttgaagt	o
183	tctgacggggaagt	o
184	tctggcgggtgaagt	o
185	ggctccggggagggaatttttgtctat	o
186	atagacaaaaattccctccccggagcc	o
187	tccatgagcttccttgagctct	RNA

- 23 -

188	tcgtcgcgtgtctccgcttctt	so
189	tcgtcgcgtgtctccgcttctt	s20
190	tcgagacattgcacaatcatctg	o
191	cagattgtgcaatgtctcga	o
192	tccatgtcgttcctgatgcg	o
193	gcgatgtcgttcctgatgct	o
194	gcgatgtcgttcctgatgcg	o
195	tccatgtcgttcgcgcgcgcg	o
196	tccatgtcgttcctgccgct	o
197	tccatgtcgttcctgtagct	o
198	gcggcgggcggcgcgcgcgc	o
199	atcaggaacgtcatgggaagc	o
200	tccatgagcttcctgagctct	p-ethoxy
201	tcaacgctt	p-ethoxy
202	tcaagctt	p-ethoxy
203	tcctgtcgttcctgtcgtt	s
204	tccatgtcgtttttgtcgtt	s
205	tcctgtcgttccttgtcgtt	s
206	tccttgtcgttcctgtcgtt	s
207	btccattccatgacgttcctgatgcttcca	os
208	tcctgtcgtttttgtcgtt	s
209	tcgtcgcgtgtctccgcttctt	s
210	tcgtcgcgtgtctgcccttctt	s
211	tcgtcgcgtgttgcgtttctt	s
212	tcctgtcgttcctgtcgttggaaacgacagg	o
213	tcctgtcgttcctgtcgtttcaacgtcaggaacgacagga	o
214	ggggtctgtcgttttgggggg	sos
215	ggggtctgtgcttttgggggg	sos
216	tccggccggttgaagt	o
217	tccggacggtgaagt	o
218	tcccgccggttgaagt	o
219	tccagacggtgaagt	o
220	tcccagacggtgaagt	o
221	tccagagcttgaagt	o
222	tccatgtzgttcctgtzgtt	s
223	tccatgacgttcctgacgtt	sos
224	ggggttgacgttttgggggg	sos
225	tccaggacttctctcaggtt	s
226	tttttttttttttttttttt	s
227	tccatgccgttcctgccgtt	s
228	tccatggcgggcctggcggg	s
229	tccatgacgttcctgccgtt	s
230	tccatgacgttcctggcggg	s
231	tccatgacgttcctgcggtt	s
232	tccatgacggtcctgacggt	s
233	tccatgcgtgcgtgcgtttt	s
234	tccatgcgttgcggtgcgtt	s
235	Btccattccattctaggcctgagctcttccat	os
236	tccatagcgttcctagcgtt	o
237	tccatgtcgttcctgtcgtt	o
238	tccatagcgatcctagcgat	o
239	tccattgcgttccttgcgtt	o
240	tccatagcgttcctagcgtt	o
241	tccatgattttcctgcagttcctgatttt	
242	tccatgacgttcctgcagttcctgacgtt	s
243	ggcggcggcggcggcggcgg	o
244	tccacgacgttttcgacgtt	s

- 24 -

245	tcgtcggttgctggttgctgt	S
246	tcgtcggttttgctggttttgctgt	S
247	tcgtcggttgctggttttgctgt	S
248	gcgtgcgttgctggttgctgt	S
249	czggczggczggczggczgg	O
250	gcggcgggcgggcgggcggg	S
251	agicccgigaacgiattcac	O
252	tgctggttgctggttgctgt	S
253	tgctggttgctggttgctgt	S
254	tgctggttgctggttgctgt	S
255	tcgtcgctcgctgt	S
256	tgctggttgctgt	S
257	cccccccccccccccc	S
258	tctagcggttttagcggtcc	SOS
259	tgcacccccaggccaccat	S
260	tcgtcgctcgctcgctcgctgt	SOS
261	tcgtcggttgctggttgctgt	SOS
262	tcgtcggttttgctggttttgctgt	SOS
263	tcgtcggttgctggttttgctgt	SOS
264	ggggaggaggaaacttcttaaaattccccagaatgttt	O
265	aaacattctgggggaattttaagaagttcctccctcccc	O
266	atgtttacttcttaaaattccccagaatgttt	O
267	aaacattctgggggaattttaagaagtaaacaat	O
268	atgtttactagacaaaattccccagaatgttt	O
269	aaacattctgggggaattttgtctagtaaacaat	O
270	aaaattgacgttttaaaaaa	SOS
271	ccccttgacgttttcccccc	SOS
272	ttttcggttggttttgctgt	
273	tcgtcggttttgctggttttgctgt	SOS
274	ctgcagcctgggac	O
275	acccgctcgtaattatagtaaaaccc	O
276	ggtacctgtggggacattgtg	O
277	agcaccgaacgtgagagg	O
278	tccatgccgttcctgccgtt	O
279	tccatgacgggtcctgacggt	O
280	tccatgccgggtcctgccgtt	O
281	tccatgcgcgtcctgcgcgt	O
282	ctgggtctttctgggtttttctgg	S
283	tcaggggtgggggaacctt	SOS
284	tccatgazgttcctagttct	O
285	tccatgatgttcctagttct	O
286	cccgaagtcatcttcttaaacctgg	O
287	ccaggttaagaggaaatgacttcggg	O
288	tcctggzggggaagt	O
289	gzggzgggzgggzggzggcc	X
290	tccatgtgcttcctgatgct	O
291	tccatgtccttcctgatgct	
292	tccatgtcgttcctagttct	
293	tccaagtagttcctagttct	O
294	tccatgtagttcctagttct	O
295	tccgcgcgttcgcgcggtt	S
296	tccggcggttcctggcggtt	S
297	tcctggaggggaagt	O
298	tcctgggggggaagt	O
299	tcctgggtggggaagt	O
300	tcgtcggttttgctggttttgctgt	O
301	ctgggtctttctgggtttttctgg	O

302	tccatgacgttcctgacgtt	o
303	tccaggacttctctcaggtt	sos
304	tzgtzgttttgtzgttttgtzgtt	o
305	btcgtcgttttgtcggttttgcgtttttt	os
306	gctatgacgttccaaggg	s
307	tcaacgtt	s
308	tccaggactttcctcaggtt	o
309	ctctctgtaggcgcgttgg	s
310	ctttccgttggacccctggg	s
311	gtccggggccaggccaaagtc	s
312	gtgcgcgcgagccgaaatc	s
313	tccatgaigtctcctgaigt	s
314	aatagtcgccataacaaaac	o
315	aatagtcgccatggcggggc	o
316	btttttccatgtcggttcctgatgctttt	os
317	tctgtcggtgaagttttt	o
318	gctagcttttagagcttttagagctt	o
319	tgtgttcccccccccccc	o
320	tgcgttcccccccccccc	o
321	tgtgttcccccccccccc	o
322	tgtgttcccccccccccc	o
323	tgcgttcccccccccccc	o
324	tgtgatcccccccccccc	o
325	tctgacgttgaagt	s
326	tctgccgttgaagt	s
327	tctgacgttgaagt	s
328	tctgagcttgaagt	s
329	tctggcggggaagt	s
330	aaaatctgtgcttttaaaaaa	sos
331	gatccagtcacagtgcctggcagaatctggat	o
332	gatccagattctgccaggtcactgtgactggat	o
333	gatccagtcacagtgcctgcagaatctggat	o
334	gatccagattctgtgagtcactgtgactggat	o
335	tgtgttcccccccccccc	o
336	tzgtggttcccccccccccc	o
337	tzgtggttcccccccccccc	o
338	tgtzgttcccccccccccc	o
339	tgtggttcccccccccccc	o
340	tgtggttcccccccccccc	o
341	tggcgttcccccccccccc	o
342	ggccttttcccccccccccc	o
343	tgtggttttgacgttttgcgtt	s
344	tgtggttttgacgttttgacgtt	s
345	cggtgttcccccccccccc	o
346	gcgtgttcccccccccccc	o
347	tgtcattcccccccccccc	o
348	acgtgttcccccccccccc	o
349	ctgtgttcccccccccccc	o
350	btttttgcgttcccccccccccc	os
351	tgtgttccccccccccccb	o
352	tgtgttttgcgttttgcgttb	o
353	tccagttccttcctcagtt	o
354	tzgtggttttgcgttttgcgtt	o
355	tctggaggggaagt	s
356	tctgaaaaggaagt	s
357	tgtgttcccccccccc	s
358	tzgtzgttttgtzgttttgtzgtt	s

359	ggggtcaagcttgagggggg	sos
360	tgtgtcttcccccccccc	s
361	tgtgtgtgtgtgtgt	s2
362	tgtgtgtgtgtgtgt	s20
363	tgtgtgtgtgtgtgt	os2
364	tcaacgttga	s
365	tcaacgtt	s
366	atagttttccatttttttac	
367	aatagtgcgcacgcgcgcac	o
368	aatagtgcgcaccccgggac	o
369	aatagtgcgcacccccccc	o
370	tgtgtgttttgtgttttgtgtt	o
371	ctgtgttttctgtgttttctgtg	s
372	ctaatttttctaatttttttctaa	s
373	tgtgtgttgggtgtgttgggtgtgtt	s
374	tgtgtgttgggtgtgttgggtt	s
375	accatggacgagctgtttcccctc	
376	tgtgtgttttgcgtgtgttt	s
377	ctgtaagtgtgttggagag	
378	gagaacgtgtgtgttcc	
379	cggtgcgactcagtctatcgg	
380	gttctcagataaagcggaaccagcaacagacacagaa	
381	ttctgtgtctgttgcgttccgctttatctgagaac	
382	cagacacagaagcccgatagacg	
383	agacagacacgaaacgaccg	
384	gtctgtcccatgatctcgaa	
385	gctggccagcttacctcccg	
386	ggggcctctataaacctggg	
387	ggggtccttgagactgcc	
388	gagaacgtgtgtgttccat	
389	tccatgtcgggtcctgatgt	
390	ctcttgcgacctggaaggta	
391	aggtacagccaggactacga	
392	accatggacgacctgtttcccctc	
393	accatggattacctttttcccctt	
394	atggaagggtccagcgttctc	o
395	agcatcaggaccgacatgga	o
396	ctctccaagctcacttacag	
397	tccctgagactgccccacctt	
398	gccacaaaacttgtccatg	
399	gtccatggcgtgcgggatga	
400	cctctataaacctgggac	
401	cggtgcgactcagtctatcgg	
402	gcgctaccggtagcctgagt	
403	cgactgccgaacaggatatcggtgatcagcactgg	
404	ccagtgtgatcaccgatatcctgttcggcagtcg	
405	ccaggttgtatagaggc	
406	tctcccagcgtacgccat	s
407	tctcccagcgtgcgtttt	s
408	tctcccagcgtgcgccat	s
409	tctcccgtcgtgcgccat	s
410	ataatcgtcgttcaagcaag	s
411	tgtgtgttttgtgttttgtgtt	s2
412	tgtgtgttttgtgttttgtgtt	s2
413	tgtgtgttttgtgttttgtgtt	s2
414	tctcgtntntcgtntntcgtnt	s
415	tctcccagcgtgcgccat	s

416	tctcccatcgctcgccat	S
417	ataatcgctgcgttcaagaaag	S
418	ataatcgacggttccccccc	S
419	tctatcgacggttcaagcaag	S
420	tcc tga cgg gg agt	S
421	tccatgacggttcctgatcc	
422	tccatgacggttcctgatcc	
423	tccatgacggttcctgatcc	
424	tcc tgg cgt gga agt	S
425	tccatgacggttcctgatcc	
426	tcgtcgctgttgctgtttctt	S
427	agcagctttagagctttagagctt	S
428	cccccccccccccccccccc	S
429	tcgtcggttttgcgttttgcgttttgcgtt	S
430	tcgtcggttttttgcgttttttgcgtt	S
431	tcgtcggtttttttttttttt	S
432	tttttcaacggttgattttt	SOS
433	ttttttttttttttttttttt	S
434	ggggtcgtcggttttggggg	
435	tcgtcggttttgcgttttggggg	
436	tcgtcgctgtctccgcttcttcttgc	S
437	tcgtcgctgtctccg	S
438	ctgtaagtgcgttggagag	
439	gagaacgctggaccttccat	
440	ccaggttgtagagggc	
441	gctagacggttagcgtga	
442	ggagctcttcgaacgccata	
443	tctccatgatggttttatcg	
444	aaggtggggcagctcagggga	
445	atcggaggactggcgcccg	
446	ttaggacaaggtctagggg	
447	accacaacgagaggaacgca	
448	ggcagtgacggctcacggg	
449	gaaccttccatgctgtt	
450	gctagacggttagcgtga	
451	gcttggagggcctgtaagt	
452	gtagccttccata	
453	cggtagccttccata	
454	cacggtagccttccata	
455	agcacggtagccttccata	
456	gaacgctggaccttccat	
457	gaccttccat	
458	tggaaccttccat	
459	gctggaccttccat	
460	acgctggaccttccat	
461	taagctctgtcaacgccagg	
462	gagaacgctggaccttccatgt	
463	tccatgtcggtcctgatgct	
464	ttcatgccttgcaaaatggcg	
465	tgctagctgtgcctgtacct	
466	agcatcaggaccgacatgga	
467	gaccttccatgtcggtcctgat	
468	acaaccacgagaacgggaac	
469	gaaccttccatgctgttccg	
470	caatcaatctgaggagaccc	
471	tcagctctgggtacttttca	
472	tggttacggtctgtcccatg	

473	gtctatcggaggactggcgc	
474	cattttacgggcgggcgggc	
475	gaggggaccattttacgggc	
476	tgtccagccgaggggacat	
477	cgggcttacggcggtgctg	
478	tggaccttctatgtcggtcc	
479	tgtcccatgtttttagaagc	
480	gtggttacggtcgtgccat	
481	cctccaaatgaaagaccccc	
482	ttgtactctccatgatggtt	
483	ttccatgctgttccggctgg	
484	gaccttctatgtcggtcctg	
485	gagaccgctcgaccttcgat	
486	ttgccccatattttagaaac	
487	ttgaaactgaggtgggac	
488	ctatcggaggactggcgcgcc	
489	cttggagggcctcccgccgg	
490	gctgaaccttccatgctgtt	
491	tagaaacagcattcttcttttagggcagcaca	
492	agatgggttctcagataaagcgga	
493	ttccgctttatctgagaaccatct	
494	gtcccagggtgtatagaggctgc	
495	gcgccagtccctccgatagac	
496	atcggaggactggcgcgccg	
497	ggctctgtcccatatttttag	
498	tttttcaacggttgagggggg	SOS
499	tttttcaacggttgatttttt	SOS
500	ggggtcaacggttgatttttt	SOS
501	gggggttttcaacggtttgagggggg	SOS
502	ggttacgggtctgtcccatat	
503	ctgtcccatatttttagaca	
504	accatcctgaggccattcgg	
505	cgtctatcgggcttctgtgtctg	
506	ggccatcccacattgaaagtt	
507	ccaaatatcgggtggtcaagcac	
508	gtgcttgaccaccgatatttgg	
509	gtgctgatcaccgatatcctgttcgg	
510	ggccaactttcaatgtgggatggcctc	
511	ttccgccaatggcctcaggatggtac	
512	tatagtccctgagactgccccaccttctcaacaacc	
513	gcagcctctatacaacctgggacggga	
514	ctatcggaggactggcgcgccg	
515	tatcggaggactggcgcgccg	
516	gatcggaggactggcgcgccg	
517	ccgaacaggatatcggtgatcagcac	
518	ttttggggtcaacggttgagggggg	
519	ggggtcaacggttgagggggg	SOS
520	cgcgcgcgcgcgcgcgcgcg	S
521	ggggcatgacgttcgggggg	SS
522	ggggcatgacgttcaaaaaa	S
523	ggggcatgagcttcgggggg	S
524	ggggcatgacgttcgggggg	SOS
525	aaaacatgacgttcaaaaaa	SOS
526	aaaacatgacgttcgggggg	SOS
527	ggggcatgacgttcaaaaaa	SOS
528	accatggacgatctgtttccctc	S
529	gccatggacgaactgttccccctc	S

530	cccccccccccccccc	SOS
531	gggggggggggggggg	SOS
532	gctgtaaaatgaatcgccg	SOS
533	ttcgggaggactcctccatt	SOS
534	tatgccgcgcccggacttat	SOS
535	ggggtaatcgatcaggggg	SOS
536	tttgagaacgctggaccttc	SOS
537	gatcgctgatctaattgctcg	SOS
538	gtcggtcctgatgctgttcc	SOS
539	tcgtcgtcagttcgtgtcg	SOS
540	ctggaccttccatgtcgg	SOS
541	gctcgttcagcgcgtct	SOS
542	ctggaccttccatgtc	SOS
543	caactgtccttcgtcga	SOS
544	cgctggaccttccatgtcgg	SOS
545	gctgagctcatgccgtctgc	SOS
546	aacgctggaccttccatgtc	SOS
547	tgcattgccgtacacagctct	SOS
548	ccttccatgtcggtcctgat	SOS
549	tactcttcggatcccttgcg	SOS
550	ttccatgtcggtcctgat	SOS
551	ctgattgctctctcgtga	SOS
552	ggcgttattcctgactcgcc	O
553	cctacgttgatgcgcccagct	O
554	ggggtaatcgatgaggggg	O
555	ttcgggaggactcctccatt	O
556	tttttttttttttttt	O
557	gggggtttttttttgggg	O
558	tttttgggggggggtttt	O
559	gggggggggggggggggt	O
560	aaaaaaaaaaaaaaaaaaaa	O
561	cccccaaaaaaaaaaccccc	O
562	aaaaaccccccccccaaaaa	O
563	tttgaattcaggactggtgaggttgag	O
564	tttgaatcctcagcggctcctcagtggc	O
565	aattctctatcggggcttctgtgtctggtgctggttccgctttat	O
566	ctagataaagcgggaaccagcaacagacagagaagccccgatagag	O
567	ttttctagagaggtgcacaatgctctgg	O
568	tttgaattccgtgtacagaagcgagaagc	O
569	tttgcggccgctagacttaacctgagagata	O
570	tttgggcccacgagagacagagacacttc	O
571	tttgggcccgccttctcgttctgtacacg	O
572	gagaacgctggaccttccat	S
573	tccatgtcggtcctgatgct	S
574	ctgtcg	S
575	tcgtga	S
576	cgtcga	S
577	agtgc	S
578	ctgtcg	O
579	agtgc	O
580	cgtcga	O
581	tcgtga	O
582	gagaacgctccagcttcgat	O
583	gctagacgtaagcgtga	O
584	gagaacgctcgaccttccat	O
585	gagaacgctggacctatccat	O
586	gctagaggttagcgtga	O

- 30 -

587	gagaacgctggacttccat	o
588	tcacgctaacgtctagc	o
589	bgctagacgttagcgtga	o
590	atggaaggctcgagcgttctc	o
591	gagaacgctggaccttcgat	o
592	gagaacgatggaccttccat	o
593	gagaacgctggatccat	o
594	gagaacgctccagcactgat	o
595	tccatgtcggtcctgctgat	o
596	atgtcctcggtcctgatgct	o
597	gagaacgctccaccttccat	o
598	gagaacgctggaccttcgta	o
599	batggaaggctccagcgttctc	o
600	tcctga	o
601	tcaacggt	o
602	aacggt	o
603	aacggtga	o
604	tcacgctaacctctagc	o
605	gagaacgctggaccttcgat	o
606	gctggaccttccat	o
607	gagaacgctggacctcatccat	o
608	gagaacgctggacgctcatccat	o
609	aacggttgaggggcat	o
610	atgcccctcaacggt	o
611	tcaacggtga	o
612	gctggaccttccat	o
613	caacggt	o
614	acaacggtga	o
615	tcacgt	o
616	tcaagcgt	o
617	tcgtca	o
618	aggatatc	o
619	tagacgtc	o
620	gacgtcat	o
621	ccatcgat	o
622	atcgatgt	o
623	atgcatgt	o
624	ccatgcat	o
625	agcgtga	o
626	tcagcgt	o
627	ccttcgat	o
628	gtgccggggtctccgggc	s
629	gctgtggggcggctcctg	s
630	btcaacggt	o
631	ftcaacggt	o
632	faacggtga	o
633	tcaacgt	s
634	aacggtg	s
635	cgacga	o
636	tcaacggt	o
637	tcgga	o
638	agaacggt	o
639	tcacgat	o
640	taaacggt	s
641	ccaacggt	s
642	gctcga	s
643	cgacgt	s

- 31 -

644	cgtcgt	s
645	acgtgt	s
646	cgttcg	s
647	gagcaagctggaccttccat	s
648	cgcgta	s
649	cgtacg	s
650	tcaccggt	s
651	caagagatgctaacaatgca	s
652	acccatcaatagctctgtgc	s
653	ccatcgat	o
654	tcgacgtc	o
655	ctagcgct	o
656	taagcgct	o
657	tcgcgaattcgcg	o
658	atggaaggtccagcgttct	o
659	actggacgttagcgtga	o
660	cgctggggctggtctgg	o
661	gtgtcggggtctccgggc	o
662	gtgccggggtctccgggc	o
663	cgccgtcgcggcggttgg	o
664	gaagttcacgttgaggggcat	o
665	atctggtgagggcaagctatg	s
666	gttgaaacccgagaacatcat	s
667	gcaacggt	o
668	gtaacggt	o
669	cgaacggt	o
670	gaaacggt	o
671	caaacggt	o
672	ctaacggt	o
673	ggaacggt	o
674	tgaacggt	o
675	acaacggt	o
676	ttaacggt	o
677	aaaacggt	o
678	ataacggt	o
679	aacgttct	o
680	tccgatcg	o
681	tccgtacg	o
682	gctagacgctagcgtga	o
683	gagaacgctggacctcatccat	o
684	gagaacgctagaccttctat	o
685	actagacgttagtgtga	o
686	cacaccttggatcaatgtcacgt	o
687	tctccatcctatggttttatcg	o
688	cgctggaccttccat	o
689	caccaccttggatcaatgtcacgt	o
690	gctagacgttagctgga	o
691	agtgcgattgcagatcg	o
692	ttttcgttttgtggtttgtggtt	
693	ttttcgttttgtcgttttgtcggt	
694	ttttgtttttgtggtttgtggtt	
695	accgcatggattctaggcca	s
696	gctagacgttagcgt	o
697	aacgctggaccttccat	o
698	tcaazggt	o
699	ccttcgat	o
700	actagacgttagtgtga	s

- 32 -

701	gctagaggttagcgtga	s
702	atggactctccagcgttctc	o
703	atcgactctcgagcgttctc	o
704	gctagacgttagc	o
705	gctagacgt	o
706	agtgcgattcgagatcg	o
707	tcagzgct	o
708	ctgattgctctctcgtga	o
709	tzaacgtt	o
710	gagaazgctggaccttccat	o
711	gctagacgttaggctga	o
712	gctacttagcgtga	o
713	gctaccttagcgtga	o
714	atcgacttcgagcgttctc	o
715	atgcactctgcagcgttctc	o
716	agtgactctccagcgttctc	o
717	gccagatgttagctgga	o
718	atcgactcgagcgttctc	o
719	atcgatcgagcgttctc	o
720	bgagaacgctcgaccttcgat	o
721	gctagacgttagctgga	sos
722	atcgactctcgagcgttctc	sos
723	tagacgttagcgtga	o
724	cgactctcgagcgttctc	o
725	gggggtcgaccttggagggggg	sos
726	gctaacgttagcgtga	o
727	cgtcgtcgt	o
728	gagaacgctggaczttccat	o
729	atcgacctacgtgcgttztc	o
730	atzgacctacgtgcgttctc	o
731	gctagazgttagcgt	o
732	atcgactctcgagzgttctc	o
733	ggggtaatgcatcagggggg	sos
734	ggctgtattcctgactgcc	s
735	ccatgctaacctctagc	o
736	gctagatgttagcgtga	o
737	cgtaccttacggtga	o
738	tccatgctggtcctgatgct	o
739	atcgactctctcgagcgttctc	o
740	gctagagcttagcgtga	o
741	atcgactctcgagtgttctc	o
742	aacgctcgaccttcgat	o
743	ctcaacgctggaccttccat	o
744	atcgacctacgtgcgttctc	o
745	gagaatgctggaccttccat	o
746	tcacgctaacctctgac	o
747	bgagaacgctccagcactgat	o
748	bgagcaagctggaccttccat	o
749	cgctagaggttagcgtga	o
750	gctagatgttaacgt	o
751	atggaaggtccacgttctc	o
752	gctagatgttagcgt	o
753	gctagacgttagtgt	o
754	tccatgacggtcctgatgct	o
755	tccatggcggtcctgatgct	o
756	gctagacgatagcgt	o
757	gctagtcatagcgt	o

758	tccatgacgttcctgatgct	o
759	tccatgtcgttcctgatgct	o
760	gctagacgttagzgt	o
761	gctaggcgttagcgt	o
762	tccatgtzggctcctgatgct	o
763	tccatgtcgggtzctgatgct	o
764	atzgactctzgagzgttctc	o
765	atggaagggtccagtgttctc	o
766	gcatgacgttgagct	o
767	gggggtcaacgttgagggggg	s
768	gggggtcaagtctgagggggg	sos
769	cgcgcgcgcgcgcgcgcgcg	o
770	cccccccccccccccccccccccc	s
771	cccccccccccccccccccccccc	s
772	tccatgtcgttcctgatcct	o
773	gctaaacgttagcgt	o
774	tccatgtcgatcctgatgct	o
775	tccatgccggtcctgatgct	o
776	aaaatcaacgttgaaaaaaa	sos
777	tccataacgttcctgatgct	o
778	tggagggtcccaccgagatcggag	o
779	cgtcgtcgtcgtcgtcgtcgt	s
780	ctgctgctgctgctgctgctg	s
781	gagaacgctccgaccttcgat	s
782	gctagatgttagcgt	s
783	gcatgacgttgagct	s
784	tcaatgctgaf	o
785	tcaacgttgaf	o
786	tcaacgttgab	o
787	gcaatattgcb	o
788	gcaatattgcf	o
789	agttgcaact	o
790	tcttcgaa	o
791	tcaacgtc	o
792	ccatgtcgggtcctgatgct	o
793	gtttttatataatttggg	o
794	tttttgtttgtcgtttttgtcgtt	o
795	ttgggggggggtt	s
796	gggggttgggggtt	s
797	ggtggtgtaggttttgg	o
798	bgagaazgctcgaccttcgat	o
799	tcaacgttaacgttaacgtt	o
800	bgagcaagztggaccttccat	o
801	bgagaazgctccagcactgat	o
802	tcaazgttgax	o
803	gzaatattgcx	o
804	tgctgcttttgcgtttttgtgctt	o
805	ctgcgttagcaatttaactgtg	o
806	tccatgacgttcctgatgct	s
807	tgcattgccgtgcattccgtacacagctct	s
808	tgcattgccgtacacagctct	s
809	tgcattcagctct	s
810	tgcgtctct	s
811	cccccccccccccccccccc	s
812	cccccccccccc	s
813	cccccccc	s
814	tgcattcagctct	sos

- 34 -

815	tgcattgccgtacacagctct	o
816	gagcaagctggaccttccat	s
817	tcaacgttaacgttaacgttaacgttaacgtt	s
818	gagaacgctcgaccttcgat	s
819	gtccccatttcccagaggaggaaat	o
820	ctagcggctgacgtcatcaagctag	o
821	ctagcttgatgacgtcagccgctag	o
822	cggctgacgtcatcaa	s
823	ctgacgtg	o
824	ctgacgtcat	o
825	attcgatcggggcggggcgag	o
826	ctcggcccgcccgatcgaat	o
827	gactgacgtcagcgt	o
828	ctagcggctgacgtcataaagctagc	s
829	ctagctttatgacgtcagccgctagc	s
830	ctagcggctgacgtcataaagctagc	s
831	ctagtggctgacgtcatcaagctag	s
832	tccaccacgtggtctatgct.	s
833	gggaatgaaagattttattataag	o
834	tctaaaaaccatctattcttaaccct	o
835	agctcaacgtcatgc	o
836	ttaacggtggtagcgggtattggtc	o
837	ttaagaccaataccgctaccaccg	o
838	gatctagtgatgagtcagccggatc	o
839	gatccggctgactcatcactagatc	o
840	tccaagacgttcctgatgct	o
841	tccatgacgtccctgatgct	o
842	tccaccacgtggctgatgct	o
843	ccacgtggacctctagc	o
844	tcagaccacgtgggtcgggtgttcctga	o
845	tcaggaaaccccgaccacgtggtctga	o
846	catttccaagatttccca	o
847	ttcctctctgcaagagact	o
848	tgtatctctctgaaggact	o
849	ataaagcgaaactagcagcagtttc	o
850	gaaactgctgctagtttcgtttat	o
851	tgcccaaagaggaaaatttgtttcatacag	o
852	ctgtatgaaacaaattttcctctttgggca	o
853	ttagggtttagggtttagggtt	s
854	tccatgagcttcctgatgct	s
855	aaaacatgacgttcaaaaaa	s
856	aaaacatgacgttcgggggg	s
857	ggggcatgagcttcgggggg	sos
858	ctaggctgacgtcatcaagctagt	o
859	tctgacgtcatctgacgttggtgacgtct	o
860	ggaattagtaatagatataagaatt	o
861	tttaccttttataaacataactaaaacaaa	o
862	gcgtttttttttgcg	s
863	atatctaatacaaacattaacaaa	o
864	tctatcccagggtgggttcctgtag	o
865	btccatgacgttcctgatgct	o
866	btccatgagcttcctgatgct	o
867	tttttttttttttf	o
868	tttttttttttttf	so
869	ctagcttgatgagctcagccgctag	o
870	ttcagttgtcttgctgcttagctaa	o
871	tccatgagcttcctgatgct	s

- 35 -

872	ctagcggtgacgtcatcaatctag	o
873	tgctagctgtgcctgtacct	s
874	atgctaaaggacgtcacattgca	o
875	tgcaatgtgacgtccttttagcat	o
876	gtaggggactttccgagctcgagatcctatg	o
877	cataggatctcgagctcggaaagtcccctac	o
878	ctgtcaggaactgcaggttaagg	o
879	cataacataggaatatattactcctcgc	o
880	ctccagctccaagaaaggacg	o
881	gaagtttctggtaagtcttcg	o
882	tgctgcttttgtgcttttgtgctt	s
883	tcgtcgttttgtggttttgtggtt	s
884	tcgtcgtttgtcgttttgtcggtt	s
885	tcctgacgttcggcgcgcgccc	s
886	tgctgcttttgtgcttttgtgctt	
887	tccatgagcttcctgagctt	s
888	tcgtcgtttcgtcgttttgacgtt	s
889	tcgtcgtttgcgtgcgtttcgctgctt	s
890	tcgcgtgcgttttgcgttttgacgtt	s
891	ttcgtcgttttgtcgttttgtcggtt	s
892	tcctgacggggaagt	s
893	tcctggcggtggaagt	s
894	tcctggcggtgaagt	s
895	tcctggcggtgaagt	s
896	tcctgacgtggaagt	s
897	gcgacgttcggcgcgcgccc	s
898	gcgacgggcgcgcgcgccc	s
899	gcggcggtcgggcgcgcgccc	s
900	gcggcggtcgggcgcgcgccc	s
901	gcgacggtcggcgcgcgccc	s
902	gcggcggtcgggcgcgcgccc	s
903	gcgacgtcgggcgcgcgccc	s
904	tcgtcgctgtctcgg	s
905	tgtgggggttttggttttgg	s
906	aggggaggggaggggagggg	s
907	tgtgtgtgtgtgtgtgtgtgt	s
908	ctctctctctctctctctctct	sos
909	ggggtcgacgtcgagggggg	s
910	atatatatatatatatatat	s
911	tttttttttttttttttttttt	s
912	tttttttttttttttttttt	s
913	tttttttttttttttttt	s
914	gctagaggggagggg	
915	gctagatgttagggg	
916	gcatgagggggagct	
917	atggaagggtccagggggctc	
918	atggactctggagggggctc	
919	atggaagggtccaaggggctc	
920	gagaaggggggaccttggat	
921	gagaaggggggaccttccat	
922	gagaagggggccagcactgat	
923	tccatgtggggcctgatgct	
924	tccatgaggggcctgatgct	
925	tccatgtggggcctgatgct	
926	atggactctccgggggtctc	
927	atggaagggtccgggggtctc	
928	atggactctggaggggtctc	

- 36 -

929	atggaggctccatggggctc	
930	atggactctgggggggttctc	
931	tccatgtgggtggggatgct	
932	tccatgcgggtggggatgct	
933	tccatgggggtcctgatgct	
934	tccatgggggtccctgatgct	
935	tccatgggggtgcctgatgct	
936	tccatgggggttctgatgct	
937	tccatcgggggcctgatgct	
938	gctagaggagtggt	
939	tttttttttttttttttt	s
940	gmgggtcaacggttgagggmagg	s
941	ggggagttcgttgaggggggg	s
942	tcgtcgtttcccccccccc	s
943	ttgggggggttttttttttttt	s
944	tttaaattttaaaattttaaata	s
945	ttggtttttttggttttttttg	s
946	tttcccttttcccttttccctc	s
947	ggggtcacgatgagggggg s	sos
948	tccatgacgttcctgacgtt	
949	tccatgacgttcctgacgtt	
950	tccatgacgttcctgacgtt	
951	tccatgacgttcctgacgtt	
952	tccatgacgttcctgacgtt	
953	tccatgacgttcctgacgtt	
954	tccatgacgttcctgacgtt	
955	tccatgacgttcctgacgtt	
956	tccatgacgttcctgacgtt	
957	tccatgacgttcctgacgtt	
958	tccatgacgttcctgacgtt	
959	gggggacgatcgtcggggg	sos
960	gggggtcgtacgacggggg	sos
961	tttttttttttttttttttt	po
962	aaaaaaaaaaaaaaaaaaaaa	po
963	cccccccccccccccccccc	po
964	tcgtcgttttgctggtttgctgtt	
965	tcgtcgttttgctggtttgctgtt	
966	tcgtcgttttgctggtttgctgtt	
967	tcgtcgttttgctggtttgctgtt	
968	gggggtcaacggttgagggggg	
969	gggggtcaacggttgagggggg	
970	gggggtcaagcgttgagggggg	
971	tgctgcttcccccccccccc	
972	ggggacgtcgacgtgggggg	sos
973	gggggtcgtcgacgagggggg	sos
974	gggggtcgacgtacgtcgagggggg	sos
975	ggggaccggtaccggtgggggg	sos
976	gggtcgacgtcgagggggg	sos
977	gggggtcgacgtcgagggggg	sos
978	ggggaacgttaacgttgggggg	sos
979	gggggtcaccggtgagggggg	sos
980	gggggtcggtcgaacgagggggg	sos

- 37 -

981	ggggacgttcgaacgtggggggg	sos
982	tcaactttga	s
983	tcaagcttga	s
984	tcacgatcgtga	s
985	tcagcatgctga	s
986	gggggagcatgctggggggg	sos
987	ggggggggggggggggggggg	sos
988	gggggacgatatcgtcggggggg	sos
989	gggggacgacgtcgtcggggggg	sos
990	gggggacgagctcgtcggggggg	sos
991	gggggacgtacgtcgggggg	sos
992	tcaacgtt	
993	tccataccggtcctgatgct	
994	tccataccggtcctaccggt	s
995	gggggacgatcgttggggggg	sos
996	ggggaacgatcgtcggggggg	sos
997	ggg ggg acg atc gtc ggg ggg	sos
998	ggg gga cga tcg tcg ggg ggg	sos
999	aaa gac gtt aaa	po
1000	aaagagcttaaa	po
1001	aaagazgttaaa	po
1002	aaattcggaaaa	po
1003	gggggtcatcgatgagggggg	sos
1004	gggggtcaacgttgagggggg	sos
1005	atgtagcttaataacaaagc	po
1006	ggatcccttgagttacttct	po
1007	ccattccacttctgattacc	po
1008	tatgtattatcatgtagata	po
1009	agcctacgtattcacccctcc	po
1010	ttcctgcaactactattgta	po
1011	atagaaggccctacaccagt	po
1012	ttacaccgggtctatggaggt	po
1013	ctaaccagatcaagtctagg	po
1014	cctagacttgatctggttag	po
1015	tataagcctcgtcggacatg	po
1016	catgtcggacgaggttata	po
1017	tgggtgggaggagtaagctc	po
1018	gagctactccccaccacca	po
1019	gccttcgatcttcgttgga	po
1020	tggacttctctttgccgtct	po
1021	atgctgtagcccagcgataa	po
1022	accgaatcagcggaaagtga	po
1023	tccatgacgttcctgacgtt	
1024	ggagaaaaccatgagctcatctgg	
1025	accacagaccagcaggcaga	
1026	gagcgtgaactgcgcgaaga	
1027	tcggtagcccttgacgcggtt	
1028	ctggagccctagccaaggat	
1029	gcgactccatcaccagcgat	
1030	cctgaagtaagaaccagatgt	

- 38 -

1031	ctgtgttatctgacatacacc	
1032	aattagccttaggtgattggg	
1033	acatctggttcttacttcagg	
1034	ataagtcataattttgggaactac	
1035	cccaatcacctaaggctaatt	
1036	ggggtcgtcgacgagggggg	SOS
1037	ggggtcgttcgaacgagggggg	SOS
1038	ggggacgttcgaacgtgggggg	SOS
1039	tcctggcgqgggaagt	S
1040	ggggaacgacgtcgttgggggg	SOS
1041	ggggaacgtacgtcgggggg	SOS
1042	ggggaacgtacgtacgttgggggg	SOS
1043	ggggtcaccggtgagggggg	SOS
1044	ggggtcgacgtacgtcgagggggg	SOS
1045	ggggaccggtaccggtgggggg	SOS
1046	gggtcgacgtcgagggggg	SOS
1047	ggggtcgacgtcgagggg	SOS
1048	ggggaacgttaacgttgggggg	SOS
1049	ggggacgtcgacgtggggg	SOS
1050	gcactcttcgaagctacagccggcagcctctgat	
1051	cggctcttccatgaggtctttgctaattcttg	
1052	cggctcttccatgaaagtcctttggacgatgtgagc	
1053	tcctgcagggttaagt	S
1054	gggggtcgttcgttgggggg	SOS
1055	gggggatgattgttgggggg	SOS
1056	gggggazgatggttgggggg	SOS
1057	gggggagctagcttgggggg	SOS
1058	ggttcttttggctcttgtct	S
1059	ggttcttttggctcttgtct	S
1060	ggttcttttggctcttatct	S
1061	ggttcttgggttcttgtct	S
1062	tggcttttggctcttgtct	S
1063	ggttcaaattggctcttgtct	S
1064	gggtcttttgggcttgtct	S
1065	tcaggacttctctcagggtttttt	S
1066	tccaaaacttctctcaaatt	S
1067	tactacttttatacttttatactt	S
1068	tgtgtgtgtgtgtgtgtgtgtg	S
1069	ttgttgttgttgttgttgttgtg	S
1070	ggctccggggaggggaatttttgtctat	S
1071	gggacgatcgtcggggggg	SOS
1072	gggtcgtcgacgaggggggg	SOS
1073	ggtcgtcgacgaggggggg	SOS
1074	gggtcgtcgtcggtggggggg	SOS
1075	ggggacgatcgtcggggggg	SOS
1076	ggggacgtcgtcggtgggggg	SOS
1077	ggggtcgacgtcgacgtcgagggggg	SOS
1078	ggggaaccgcggttggggggg	SOS
1079	ggggacgacgtcggtggggggg	SOS
1080	tcgtcgtcgtcgtcggtggggggg	SOS

- 39 -

1081	tcctgccggggaagt	s
1082	tcctgcaggggaagt	s
1083	tcctgaaggggaagt	s
1084	tcctggcgggcaagt	s
1085	tcctggcgggtaagt	s
1086	tcctggcgggaaagt	s
1087	tccgggcggggaagt	s
1088	tcggggcggggaagt	s
1089	tccgggcggggaagt	s
1090	gggggacgttggggg	s
1091	gggggtttttttttggggg	sos
1092	ggggccccccccggggg	sos
1093	ggggttgttgttgttggggg	sos

Nucleic acids having modified backbones also are included in the class of nucleic acids having antiangiogenic properties. Modified backbone nucleic acids include those having phosphorothioate, methylphosphonate, methylphosphorothioate, p-ethoxy and/or phosphorodithioate internucleotide or internucleoside bonds. Chimeric oligonucleotides having mixtures of modified and/or unmodified backbones also are included in the invention.

In the case when an antiangiogenic nucleic acid is administered in conjunction with a nucleic acid vector, it is preferred that the backbone of the antiangiogenic nucleic acid be a chimeric combination of phosphodiester and phosphorothioate bonds (or other modification of the internucleotide bonds). This is because the uptake of the plasmid vector by the cell may be hindered by the presence of completely phosphorothioate oligonucleotide. Thus when both a vector and an oligonucleotide are delivered to a subject, it is preferred that the oligonucleotide have chimeric or phosphorothioate internucleotide bonds and that the plasmid be associated with a vehicle that delivers it directly into the cell, thus avoiding the need for cellular uptake. Such vehicles are known in the art and include, for example, liposomes, electroporation devices and gene guns.

For use in the instant invention, the antiangiogenic nucleic acids can be synthesized *de novo* using any of a number of procedures well known in the art. Such compounds are referred to as "synthetic nucleic acids." For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4051-4054, 1986; Froehler *et al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986, Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986, Gaffney *et al.*, *Tet. Let.* 29:2619-2622, 1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market.

Alternatively, nucleic acids can be produced on a large scale in plasmids, (see, e.g., Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. Nucleic acids can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases. Nucleic acids prepared in this manner are referred to as isolated nucleic acids. The term "antiangiogenic nucleic acid" encompasses both synthetic and isolated antiangiogenic nucleic acids.

For use *in vivo*, nucleic acids are preferably relatively resistant to degradation (e.g., are stabilized). A "stabilized nucleic acid molecule" as used herein means a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Antiangiogenic nucleic acids that are tens to hundreds of kilobases long are relatively resistant to *in vivo* degradation. For shorter antiangiogenic nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of a nucleic acid is self-complementary to an upstream region of the same nucleic acid, so that it can fold back and form a stem/loop structure by internal self-hybridization, then the nucleic acid may be stabilized and therefore may exhibit more *in vivo* activity.

Alternatively, nucleic acid stabilization can be accomplished via backbone modifications. Preferred stabilized nucleic acids of the instant invention have a modified backbone. It has been demonstrated that modification of the nucleic acid backbone provides enhanced activity of the antiangiogenic nucleic acids when administered *in vivo*. One type of modified backbone is a phosphate backbone modification. For example, antiangiogenic nucleic acids including at least two phosphorothioate linkages at the 5' end of the oligonucleotide and multiple phosphorothioate linkages at the 3' end, preferably 5 or more, can in some circumstances protect the nucleic acid from degradation by intracellular exo- and endo-nucleases and thereby provide maximal activity. Other phosphate modified nucleic acids include phosphodiester modified nucleic acids, combinations of phosphodiester and phosphorothioate nucleic acids, methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy and combinations thereof. Some of these combinations in CpG nucleic acids and their particular effects on immune cells is discussed in more detail in PCT Published Patent Applications PCT/US95/01570 and PCT/US97/19791, the entire contents of which are hereby incorporated by reference. Although not intending to be bound by any

particular theory, it is believed that these modified nucleic acids may have increased activity relative to unmodified nucleic acids due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.

Modified backbone nucleic acids, such as those having phosphorothioates bonds may be synthesized using automated techniques employing, for example, phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863. Alkylphosphotriesters, in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574, can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other nucleic acid backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., *Chem. Rev.* 90:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Another type of modified backbone, useful according to the invention, is a peptide nucleic acid. The backbone is composed of aminoethylglycine and supports bases which provide the nucleic acid character. The backbone does not include any phosphate and thus may optionally have no net charge. The lack of charge allows for stronger DNA-DNA binding because the charge repulsion between the two strands does not exist. Additionally, because the backbone has an extra methylene group, the oligonucleotides are enzyme/protease resistant. Peptide nucleic acids can be purchased from various commercial sources, e.g., Perkin Elmer, or synthesized de novo.

Another class of backbone modifications include 2'-O-methylribonucleosides (2'-O-Me). These types of substitutions are described extensively in the literature and in particular with respect to their immunostimulating properties in Zhao et al., *Bioorganic and Medicinal Chemistry Letters*, 1999, 9:24:3453. Zhao et al. describes methods of preparing 2'-O-Me modifications to nucleic acids.

The nucleic acid molecules of the invention may include naturally-occurring or synthetic purine or pyrimidine heterocyclic bases as well as modified backbones. Purine or pyrimidine heterocyclic bases include, but are not limited to, adenine, guanine, cytosine, thymidine, uracil, and inosine. Other representative heterocyclic bases are disclosed in US Patent No. 3,687,808, issued to Merigan, et al. The terms "purines" or "pyrimidines" or "bases" are used herein to refer to both naturally-occurring or synthetic purines, pyrimidines or bases.

- 42 -

Other stabilized nucleic acids include non-ionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acids which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either
5 or both termini have also been shown to be substantially resistant to nuclease degradation.

The antiangiogenic nucleic acids having backbone modifications useful according to the invention in some embodiments are S- or R-chiral antiangiogenic nucleic acids. An "S chiral antiangiogenic nucleic acid" as used herein is an antiangiogenic nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a
10 plurality of the chiral centers have S chirality. An "R chiral antiangiogenic nucleic acid" as used herein is an antiangiogenic nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a plurality of the chiral centers have R chirality. The backbone modification may be any type of modification that forms a chiral center. The modifications include but are not limited to phosphorothioate,
15 methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy, 2'-O-Me and combinations thereof.

The chiral antiangiogenic nucleic acids must have at least two nucleotides within the nucleic acid that have a backbone modification. All or less than all of the nucleotides in the nucleic acid, however, may have a modified backbone. Of the nucleotides having a modified
20 backbone (referred to as chiral centers), a plurality have a single chirality, S or R. A "plurality" as used herein refers to an amount greater than 50%. Thus, less than all of the chiral centers may have S or R chirality as long as a plurality of the chiral centers have S or R chirality. In some embodiments at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the chiral centers have S or R chirality. In other embodiments at least 55%, 60%,
25 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides have backbone modifications.

The S- and R- chiral antiangiogenic nucleic acids may be prepared by any method known in the art for producing chirally pure oligonucleotides. Stec et al teach methods for producing stereopure phosphorothioate oligodeoxynucleotides using an oxathiaphospholane.
30 (Stec, W.J., et al., 1995, *J. Am. Chem. Soc.*, 117:12019). Other methods for making chirally pure oligonucleotides have been described by companies such as ISIS Pharmaceuticals. US Patents which disclose methods for generating stereopure oligonucleotides include 5,883,237;

- 43 -

5,837,856; 5,599,797; 5,512,668; 5,856,465; 5,359,052; 5,506,212; 5,521,302; and 5,212,295, each of which is hereby incorporated by reference in its entirety.

As used herein, administration of an antiangiogenic nucleic acid is intended to embrace the administration of one or more antiangiogenic nucleic acids which may or may not differ in terms of their profile, sequence, backbone modifications and biological effect. As an example, CpG nucleic acids and T-rich nucleic acids may be administered to a single subject along with other antiangiogenic medicament(s), such as endostatin or angiostatin. In another example, a plurality of CpG nucleic acids which differ in nucleotide sequence may also be administered to a subject.

The invention encompasses the administration of the antiangiogenic nucleic acids along with other medicaments in order to provide a synergistic effect useful in the prevention and/or treatment of conditions that involve unwanted angiogenesis, such as cancer. Accordingly, methods for inhibition of angiogenesis are provided. The methods include the administration of at least one antiangiogenic nucleic acid formulated for administration to a subject. Non-nucleic acid antiangiogenesis molecules also can be administered to the subject, including, but not limited to endogenous angiogenesis inhibitors including PD 174073 and PD 166285 (Parke-Davis), SU5416 and SU6668 (Sugen), ZD 4190 and ZD 6474 (Zeneca), PTK 787 (also known as CGP79787 or ZK22584) (Novartis), Anti-VEGF mAb (Genentech), Anti-KDR mAb (ImClone), RPI 4610 (Ribozyme), TNP 470 (Abbott/TAP), AG 3340 (Agouron), Marimastat (British Biotech), Bay 12-9566 (Bayer), Neovastat (Aeterna), BMS 275291 (Bristol Myers-Squibb), CGS 27023A (Novartis), D1927 Chiroscience), D2163 (Chiroscience), Isoquinolines (Pfizer), Vitaxin (IXSYS), S-137 (Searle), S-836 (Searle), SM256 (Dupont), SG545 (Dupont), Angiostatin (EntreMed), Endostatin (EntreMed), Thalidomide (EntreMed), Squalamine (Magainin), CAI (National Cancer Institute), CM-101 (CarboMed), U-995 (Gwo-Chyang GMP), Combretastatin A-4 (Oxigene), platelet factor-4, vasostatin, thrombospondin, tissue inhibitors of metalloproteinases (TIMPs), STI412 (Sun and McMahon, *Drug Discov. Today* 5(8):344-353, 2000; Klohs and Hamby, *Curr. Opin. Biotechnol.* 10:544-549, 1999), fumagillin, non-glucocorticoid steroids and heparin and heparin fragments and antibodies to one or more angiogenic peptides such as α -FGF, β -FGF, VEGF, IL-8, and GM-CSF. Some of the foregoing may be administered in the form of nucleic acids encoding proteins; in each case the active agent is a protein and not the nucleic acid encoding the protein.

- 44 -

The antiangiogenic nucleic acid molecules of the invention can be administered concurrently with, or sequentially with, the non-nucleic acid antiangiogenesis molecules described above. Coadministration may be in the form of administration of a composition containing both kinds of antiangiogenic agents, or a plurality of compositions, each of which may contain one or more than one of the antiangiogenic agents.

The invention may be used in the treatment of cancer, but is not so limited. In these methods, an effective amount of at least one antiangiogenic nucleic acid is administered to a subject having cancer, or in other instances a subject at risk of developing cancer. Other non-nucleic acid antiangiogenesis molecules also can be administered, as described above. In addition, in certain embodiments of the invention, anticancer molecules are administered in combination with the antiangiogenesis molecules.

The compounds useful in the invention may be delivered in a mixture with anti-proliferative agents (particularly anticancer agents) which are not antiangiogenic nucleic acids. One of ordinary skill in the art is familiar with a variety of anti-proliferative agents which are used in the medical arts to treat proliferative diseases such as cancer. These anticancer agents may act by directly killing cells, such as cancer cells (i.e., direct action anti-cancer agents), or alternatively they may act by sensitizing cells to direct action anti-cancer agents (i.e., indirect action anti-cancer agents). Those of skill in the art will recognize the distinction and are familiar with agents of either class. Anticancer agents include, but are not limited to, the following sub-classes of compounds:

Antineoplastic agents such as: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Adriamycin; Aldesleukin ; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin ; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrone Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine ; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin ; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide ; Cytarabine ; Dacarbazine; DACA (N-[2-(Dimethyl-amino)ethyl]acridine-4-carboxamide); Dactinomycin; Daunorubicin Hydrochloride; Daunomycin; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride ; Elsamitrucin; Enloplatin; Enpromate; Epirubicin

Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; 5-FdUMP; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; 5 Gemcitabine Hydrochloride; Gold Au 198 ; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a ; Interferon Alfa-2b ; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a ; Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride ; Lanreotide Acetate; Letrozole; Leuprolide Acetate ; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; 10 Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melfalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedopa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin 15 Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin ; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol ; Safingol Hydrochloride ; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; 20 Strontium Chloride Sr 89; Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Thymitaq; Tiazofurin; Tirapazamine; Tomudex; TOP-53; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil 25 Mustard; Uredopa; Vapreotide; Verteporfin; Vinblastine; Vinblastine Sulfate; Vincristine; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinatate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride; 2-Chlorodeoxyadenosine; 2'-Deoxyformycin; 9-aminocamptothecin; raltitrexed; N-propargyl-5,8-dideazafolic acid; 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine; 2-chloro-2'-deoxyadenosine; anisomycin; 30 trichostatin A; hPRL-G129R; CEP-751; linomide.

Other anti-neoplastic compounds include: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin;

ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin
5 glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauroporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide;
10 bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives (e.g., 10-hydroxy- camptothecin); canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetorelix; chlorins;
15 chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplatan; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexifosfamide;
20 dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; discodermolide; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epothilones including desoxyepothilones (A, R = H; B, R = Me); epithilones; epristeride; estramustine
25 analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide; etoposide 4'-phosphate (etopofos); exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;
30 heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofofene; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact; irsogladine;

isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N
 triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole;
 leukemia inhibiting factor; leukocyte alpha interferon; leuprolide + estrogen + progesterone;
 leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide;
 5 lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol;
 lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline;
 lytic peptides; maitansine; mannostatin A; marimastat; masoprocil; maspin; matrilysin
 inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin;
 methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim;
 10 mismatched double stranded RNA; mithracin; mitoguazone; mitolactol; mitomycin
 analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene;
 molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid
 A + myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple
 tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial
 15 cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin;
 nagestip; naloxone + pentazocine; napavin; naphterpin; nartograstim; nedaplatin;
 nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide
 modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone;
 oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer;
 20 ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues; paclitaxel derivatives;
 palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin;
 pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole;
 perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase
 inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;
 25 plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine
 complex; podophyllotoxin; porfimer sodium; porfiromycin; propyl bis-acridone;
 prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C
 inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors;
 purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated
 30 hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl
 protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated;
 rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine;
 romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A;

- 48 -

sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;

5 spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide;

10 tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; tricyriline; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase

15 inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatein; zilascorb; zinostatin stimalamer.

Anti-cancer Supplementary Potentiating Agents: Tricyclic anti-depressant drugs (e.g.,

20 imipramine, desipramine, amitriptyline, clomipramine, trimipramine, doxepin, nortriptyline, protriptyline, amoxapine and maprotiline); non-tricyclic anti-depressant drugs (e.g., sertraline, trazodone and citalopram); Ca^{++} antagonists (e.g., verapamil, nifedipine, nitrendipine and caroverine); Calmodulin inhibitors (e.g., prenylamine, trifluoroperazine and clomipramine); Amphotericin B; Triparanol analogues (e.g., tamoxifen); antiarrhythmic drugs (e.g.,

25 quinidine); antihypertensive drugs (e.g., reserpine); Thiol depleters (e.g., buthionine and sulfoximine) and Multiple Drug Resistance reducing agents such as Cremaphor EL. The compounds of the invention also can be administered with cytokines such as granulocyte colony stimulating factor.

Antiproliferative agent: Piritrexim Isethionate.

30 Radioactive agents: Fibrinogen I 125 ; Fludeoxyglucose F 18 ; Fluorodopa F 18 ; Insulin I 125; Insulin I 131; Iobenguane I 123; Iodipamide Sodium I 131 ; Iodoantipyrine I 131 ; Iodocholesterol I 131 ; Iodohippurate Sodium I 123 ; Iodohippurate Sodium I 125 ; Iodohippurate Sodium I 131 ; Iodopyracet I 125 ; Iodopyracet I 131 ; Iofetamine

- 49 -

Hydrochloride I 123 ; Iomethin I 125 ; Iomethin I 131 ; Iothalamate Sodium I 125 ;
Iothalamate Sodium I 131 ; Iotyrosine I 131; Liothyronine I 125; Liothyronine I 131;
Merisoprol Acetate Hg 197; Merisoprol Acetate Hg 203; Merisoprol Hg 197 ;
Selenomethionine Se 75 ; Technetium Tc 99m Antimony Trisulfide Colloid; Technetium Tc
5 99m Bicisate ; Technetium Tc 99m Disofenin ; Technetium Tc 99m Etidronate ; Technetium
Tc 99m Exametazime ; Technetium Tc 99m Furifosmin ; Technetium Tc 99m Gluceptate ;
Technetium Tc 99m Lidofenin ; Technetium Tc 99m Mebrofenin ; Technetium Tc 99m
Medronate ; Technetium Tc 99m Medronate Disodium; Technetium Tc 99m Mertiatide ;
Technetium Tc 99m Oxidronate ; Technetium Tc 99m Pentetate; Technetium Tc 99m
10 Pentetate Calcium Trisodium; Technetium Tc 99m Sestamibi ; Technetium Tc 99m
Siboroxime ; Technetium Tc 99m Succimer ; Technetium Tc 99m Sulfur Colloid ;
Technetium Tc 99m Teboroxime ; Technetium Tc 99m Tetrofosmin ; Technetium Tc 99m
Tiatide; Thyroxine I 125; Thyroxine I 131; Tolpovidone I 131 ; Triolein I 125; Triolein I 131.

The present invention further includes nucleic acid molecules formulated into a
15 pharmaceutical composition for the inhibition of angiogenesis. The pharmaceutical
compositions of the invention include those suitable for oral, rectal, nasal, topical (including
buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular,
intravenous, intratumoral and intradermal) administration.

The nucleic acids are delivered in effective amounts. In general, the term "effective
20 amount" of a nucleic acid refers to the amount necessary or sufficient to realize a desired
biologic effect. Specifically, the effective amount is that amount that reduces the rate or
inhibits altogether angiogenesis. For instance, when the subject bears a tumor having a blood
supply, an effective amount is that amount which decreases or eliminates all together the
blood supply to the tumor. Additionally, an effective amount may be that amount which
25 prevents an increase or causes a decrease in new blood vessels, e.g., those vessels supplying a
tumor. The effective amount may vary depending upon whether the antiangiogenic nucleic
acid is used alone or in combination with other therapeutics, or in single or multiple dosages.
In some instances, it is envisioned that the combination of antiangiogenic nucleic acids with
other therapeutic agents (which are themselves not antiangiogenic nucleic acids) can result in
30 a synergism between the two compound classes, and thereby would require less of one or both
compounds in order to observe the desired biologic effect. Combined with the teachings
provided herein, by choosing among the various active compounds and weighing factors such
as potency, relative bioavailability, patient body weight, severity of adverse side-effects and

- 50 -

preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. As mentioned above, the effective amount for any particular application can vary depending on such factors as the type of condition having unwanted angiogenesis being treated or prevented, the particular nucleic acid being administered (e.g. the number of unmethylated CpG motifs or their location in the nucleic acid), the use of another antiangiogenesis agent, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular nucleic acid molecule without necessitating undue experimentation.

Subject doses of the compounds described herein typically range from about 0.1 μ g to 10 mg per administration, which depending on the application could be given hourly, daily, weekly, or monthly and any other amount of time therebetween. More typically doses range from about 10 μ g to 5 mg per administration, and most typically from about 100 μ g to 1 mg, with 2 - 4 administrations being spaced hours, days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any compound described herein the therapeutically effective amount can be initially determined from animal models, e.g. the animal models described herein or those well known in the art. A therapeutically effective dose can also be determined from human data for CpG nucleic acids which have been tested in humans (human clinical trials have been initiated and the results publicly disseminated) and for compounds which are known to exhibit similar pharmacological activities, such as other antiangiogenesis agents. Higher doses may be required for parenteral administration, as described above. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

For use in therapy, an effective amount of the nucleic acid can be administered to a subject by any mode that delivers the nucleic acid to a subject. "Administering" the

- 51 -

pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. Some routes of administration include but are not limited to oral, intranasal, intratracheal, inhalation, ocular, vaginal, rectal, parenteral (e.g. intramuscular, intradermal, intravenous, intratumoral or subcutaneous injection) and direct injection.

5 For oral administration, the compounds (i.e., antiangiogenic nucleic acid molecules and optionally other antiangiogenesis agents) can be delivered alone without any pharmaceutical carriers or formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. The term "pharmaceutically-acceptable carrier" means one or more compatible solid or liquid filler, diluents or
10 encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction
15 which would substantially impair the desired pharmaceutical efficiency.

Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules,
20 after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired,
25 disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions.

Dragee cores may be provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl
30 pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray, from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.* gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers

or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

5 The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

10 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

15 The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

20 Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions may also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, 25 sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

30 The nucleic acid molecules and/or agents (e.g., antiangiogenesis agents, anticancer agents) may be administered per se (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the

- 54 -

following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

The nucleic acids or other therapeutics useful in the invention may be delivered in mixtures with additional antiangiogenesis agent(s). A mixture may consist of several antiangiogenesis agents in addition to the nucleic acid.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular nucleic acid molecules or other agents selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compounds into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S.

- 55 -

Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients;

5 partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In
10 addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation. In still other embodiments, the agents and nucleic acids are formulated with GELFOAM, a commercial product consisting of modified collagen fibers that degrade slowly.

The nucleic acid may be directly administered to the subject or may be administered in conjunction with a pharmaceutically acceptable carrier or a delivery vehicle. The nucleic acid
15 and optionally other therapeutic agents may be administered alone (e.g. in saline or buffer) or using any delivery vehicles known in the art. One type of delivery vehicle is referred to herein as a nucleic acid delivery complex. A "nucleic acid delivery complex" shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell
20 (e.g. dendritic cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with: a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to reduce significant uncoupling prior to internalization by
25 the target cell. However, the complex may be cleavable under appropriate conditions within the cell so that the nucleic acid may be released in a functional form.

The nucleic acid molecules may be delivered by non-invasive methods as described above. Non-invasive delivery of compounds is desirable for treatment of children, elderly, animals, and even adults and also to avoid the risk of needle-stick injury. Delivery vehicles
30 for delivering compounds to mucosal surfaces have been described and include but are not limited to: cochleates, emulsomes, ISCOMs, liposomes, live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, *Bacillus calmatte-guerin*, *Shigella*, *Lactobacillus*), live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex), microspheres, nucleic acid vaccines,

polymers (e.g. carboxymethylcellulose, chitosan), polymer rings, proteosomes, sodium fluoride, transgenic plants, virosomes, and virus-like particles.

Examples

5 1. Background

1.1. *Angiogenesis*

Angiogenesis describes the active biological process of blood vessel formation from pre-existing microvasculature (1, 2). In multi-celled organisms this is a highly organized and tightly regulated process that occurs normally during development, inflammation, and tissue
10 repair. The importance of angiogenesis is reflected in the need of mammalian cells for oxygen and nutrients. Mammalian cells must be within a 200 μ M distance of blood vessels, which is the diffusion limit for oxygen (3). Thus the overall driving factor for angiogenesis is the requirement for oxygen and nutrients. The normal regulation of angiogenesis is mediated by the balance between pro- and anti-angiogenic factors that are released in the tissues and are
15 influenced by local environmental factors.

1.2. *Angiogenesis and neoplasms*

In a neoplastic situation, the balances of these pro- and anti-angiogenic factors are generally skewed in favor of angiogenesis. In this setting, angiogenesis is generally a highly
20 disorganized and loosely regulated process that is an absolute requirement for the continued growth of neoplasms (3). Further, there is a direct correlation between the extent of vascularization found in neoplasms and the potential for metastasis (4).

1.3. *Angiogenesis and chemokines*

25 There are a number of pro- and anti-angiogenic factors that have been described to date (3). The focus of this analysis will be on the chemokines interferon- γ -inducible protein (IP-10) and monokine induced by interferon- γ (MIG). Chemokines are a collection of cytokines that possess chemoattracting properties (for review see (5)). Chemokines are classified on the basis of the motif displayed by the first two cysteine residues present in the
30 protein (CXC, CC, C, or CX3C), and they signal through G-protein coupled, seven-transmembrane receptors. Initially identified for their influence on hemopoietic cell migration, chemokines are now known to influence a number of physiological and pathological process including angiogenesis and angiostasis (5).

- 57 -

IP-10 and MIG belong to a subset of the family of CXC chemokines (2) that bind the chemokine receptor CXCR3 (6). The CXC chemokine family can be further subdivided based on the presence or absence of a Glu-Leu-Arg or ELR motif at the NH₂ terminus of the chemokine. CXC chemokines that contain the ELR motif are potent promoters of angiogenesis whereas CXC chemokines that lack the ELR motif, as is the case for IP-10 and MIG, are potent inhibitors of angiogenesis (2).

2. Material and Methods

2.1. ODNs

10 ODN 1826 (TCCATGACGTTTCCTGACGTT; SEQ ID NO: 69)

2.2 Matrigel® - (BD)

Matrix solution is liquid at 4°C and solidifies at room temperature. When injected *in vivo* Matrigel solidifies to form a plug. Matrigel allows for the delivery of angiogenic promoters such as basic fibroblastic growth factor (bFGF) for the induction of angiogenesis. Plugs can then be removed to evaluate the level of angiogenesis as identified by the concentration of hemoglobin present. This system can be used to evaluate the anti-angiogenic potential of different compounds.

2.3 Hemoglobin quantification kit

Drabkin method reagent kit (Sigma)

20 2.4 Protein quantification

Protein quantification kit (BioRad)

2.5 Experimental design

For each group of 5 mice, the Matrigel was prepared as follows:

Group 1 - Matrigel alone.

25 3.5 mL of Matrigel

500 µL/mouse was injected subcutaneously (SC) right of center of the abdomen

Group 2 - Matrigel + bFGF (150ng/mL) + heparin (40 units/mL)

52.5 µL bFGF (10µg/mL)

23.2 µL heparin (6039 units/mL)

30 3.42 mL Matrigel

500 µL/mouse was injected SC right of center of the abdomen

Group 3 - Matrigel + bFGF (150 ng/mL) + heparin (40 units/mL) + oligo 1826 (1mg/mL)

- 58 -

52.5 μ L bFGF (10 μ g/mL)

23.2 μ L heparin (6039 units/mL)

233 μ L oligo 1826 (15mg/mL)

3.19 mL Matrigel

5 500 μ L/mouse was injected SC right of center of the abdomen

Group 4 - Matrigel + bFGF (150ng/mL) + heparin (40 units/mL)

52.5 μ L bFGF (10 μ g/mL)

23.2 μ L heparin (6039 units/mL)

3.42 mL Matrigel

10 500 μ L/mouse was injected SC right of center of the abdomen

This group received daily SC injections, for 6 days, of 100 μ L of ODN 1826 (1mg/mL) on the opposite flank from the Matrigel plug.

2.6 Determination of Hemoglobin and total protein content of Matrigel plugs

On day 6 the animals were euthanised and the Matrigel plugs collected. The plugs were
15 placed in 0.3 mL of sterile PBS and placed at 4°C over night to allow the Matrigel to liquify.
The hemoglobin and total protein content of the Matrigel plugs was determined using the
methods described above. The hemoglobin content of the Matrigel plugs was expressed as
(mg/mL)/mg of total protein.

20 3. Preliminary Results

When angiogenic factors were added to the Matrigel (Group 2), there was a significant
increase in the amount of hemoglobin present in the Matrigel plug at 6 days when compared
to Matrigel alone (Group 1) ($p < 0.05$). (See Figure 1.)

When CpG was included in the Matrigel plug along with the angiogenic factors
25 (Group 3), there was a greater than 2 fold decrease in the amount of hemoglobin present in the
Matrigel plug at 6 days when compared to the Matrigel containing the angiogenic factors
(Group 2). (See Figure 1.)

When CpG was administered daily by subcutaneous injection, rather than present in
the Matrigel plug, to the mouse in the flank opposite to the Matrigel plug which contained
30 angiogenic factors (Group 4) there was no significant difference in the amount of hemoglobin
present in the Matrigel plug at 6 days when compared to Matrigel containing the angiogenic
factors (Group 2). (See Figure 1.)

- 59 -

These preliminary results suggest that the inclusion of CpG ODN directly within the Matrigel (Group 3) had a negative influence on angiogenesis. Although daily delivery of CpG to the opposite flank from the Matrigel plug did not appear to influence angiogenesis, it is possible that CpG administered intravenously or subcutaneously in a region closer to the plug (and accordingly tumor mass) would manifest anti-angiogenic activity. CpG ODN may have to be present in the vicinity of active angiogenesis in order to have a negative influence.

4. References

1. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. *Nat Med.* 6: 389-95.
- 10 2. Belperio, J. A., et al. 2000. CXC chemokines in angiogenesis. *J Leukoc Biol.* 68: 1-8.
3. Carmeliet, P., R. K. Jain. 2000. Angiogenesis in cancer and other diseases. *Nature.* 407: 249-57.
4. Zetter, B. R. 1998. Angiogenesis and tumor metastasis. *Annu Rev Med.* 49: 407-24.
5. Rossi, D., A. Zlotnik. 2000. The biology of chemokines and their receptors. *Annu Rev*
- 15 *Immun.* 18: 217-42.
6. Loetscher, M., et al. 1996. Chemokine receptor specific for IP10 and MIG: structure, function, and expression in activated T-lymphocytes. *J Exp Med.* 184: 963-9.
7. Coughlin, C. M., et al. 1998. Tumor cell responses to IFN γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. *Immunity.* 9: 25-34.
- 20 8. Strasly, M., et al. 2001. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. *J Immunol.* 166: 3890-9.
9. Kanegane, C., et al. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. *J Leukoc Biol.* 64: 384-92.

Equivalents

It should be understood that the preceding is merely a detailed description of certain preferred embodiments. It therefore should be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. It is intended that the invention encompass all such modifications within the scope of the appended claims. All references, patents and patent applications and publications that are cited or referred to in this application are incorporated in their entirety herein by reference.

WO 02/053141

PCT/US01/48458

- 60 -

I claim:

- 61 -

Claims

1. A method of inhibiting angiogenesis in a subject in need of such treatment comprising administering to the subject at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis in the subject.

5

2. The method of claim 1, wherein the at least one antiangiogenic nucleic acid molecule comprises at least one sequence set forth as SEQ ID NOs: 1-1093.

10

3. The method of claim 1, wherein two or more antiangiogenic nucleic acid molecules are administered.

4. The method of claim 1, further comprising administering to the subject at least one non-nucleic acid angiogenesis inhibitor molecule.

15

5. The method of claim 1, wherein the angiogenesis is associated with a condition selected from the group consisting of a solid tumor growth, a tumor metastasis, and a precancerous lesion.

20

6. The method of claim 1, wherein the nucleic acid is a CpG nucleic acid having an unmethylated CpG motif.

7. The method of claim 1, wherein the nucleic acid is a T-rich nucleic acid.

8. The method of claim 1, wherein the nucleic acid is a poly G nucleic acid.

25

9. The method of claim 1, wherein the nucleic acid is isolated.

10. The method of claim 1, wherein the nucleic acid does not encode a protein having antiangiogenesis activity.

30

11. The method of claim 1, wherein the nucleic acid has a modified backbone.

- 62 -

12. The method of claim 11, wherein the modified backbone is a phosphate backbone modification.

13. The method of claim 11, wherein the modified backbone is a peptide modified
5 oligonucleotide backbone.

14. The method of claim 1, further comprising administering to the subject at least one anticancer agent.

10 15. The method of claim 1, further comprising administering to the subject at least one antiarthritis agent.

16. The method of claim 6, wherein the CpG nucleic acid comprises:



15 wherein C is unmethylated, and wherein X_1X_2 and X_3X_4 are nucleotides.

17. The method of claim 16, wherein the $5' X_1 X_2 CGX_3 X_4 3'$ sequence is a non-palindromic sequence.

20 18. The method of claim 16, wherein the CpG nucleic acid has 8 to 100 nucleotides.

19. The method of claim 16, wherein X_1X_2 are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, TpG, ApG, CpG,
25 TpC, ApC, CpC, TpA, ApA, and CpA.

20. The method of claim 16, wherein X_1X_2 are selected from the group consisting of GpA and GpT and X_3X_4 are TpT.

30 21. The method of claim 16, wherein X_1X_2 are both purines and X_3X_4 are both pyrimidines.

22. The method of claim 16, wherein X_2 is a T and X_3 is a pyrimidine.

23. The method of claim 16, wherein the CpG nucleic acid is 8 to 40 nucleotides in length.

24. The method of claim 16, wherein the CpG nucleic acid has a sequence selected from
5 the group consisting of SEQ ID NOs: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58,
64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-
150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-
240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-
307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369,
10 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-
443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488,
489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-
576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664,
666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763,
15 766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818,
820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904,
and 909-913.

25. The method of claim 7, wherein the T-rich nucleic acid is a poly T nucleic acid
20 comprising

5' TTTT 3'.

26. The method of claim 25, wherein the poly T nucleic acid comprises

5' X₁ X₂TTTTX₃ X₄ 3'

25 wherein X₁, X₂, X₃ and X₄ are nucleotides.

27. The method of claim 25, wherein the T rich nucleic acid comprises a plurality of poly
T nucleic acid motifs.

30 28. The method of claim 26, wherein X₁X₂ is TT.

29. The method of claim 26, wherein X₃X₄ is TT.

- 64 -

30. The method of claim 26, wherein X_1X_2 is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

31. The method of claim 26, wherein X_3X_4 is selected from the group consisting of TA,
5 TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

32. The method of claim 25, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 25% T.

10 33. The method of claim 7, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 25% T.

34. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 30% T.

15 35. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 50% T.

36. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide
20 composition of greater than 60% T.

37. The method of claim 33, wherein the T rich nucleic acid comprises a nucleotide composition of greater than 80% T.

25 38. The method of claim 7, wherein the T rich nucleic acid comprises at least 20 nucleotides.

39. The method of claim 7, wherein the T rich nucleic acid comprises at least 24 nucleotides.

30 40. The method of claim 8, wherein the poly G nucleic acid comprises:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides.

- 65 -

41. The method of claim 40, wherein at least one of X₃ and X₄ are a G.

42. The method of claim 40, wherein both of X₃ and X₄ are a G.

43. The method of claim 8, wherein the poly G nucleic acid comprises the following formula:



wherein N represents between 0 and 20 nucleotides.

44. The method of claim 8, wherein the poly G nucleic acid comprises the following formula:



wherein N represents between 0 and 20 nucleotides.

45. The method of claim 8, wherein the poly G nucleic acid is free of unmethylated CG dinucleotides

46. The method of claim 45, wherein the poly G nucleic acid is selected from the group consisting of SEQ ID NOs: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938.

47. The method of claim 8, wherein the poly G nucleic acid includes at least one unmethylated CG dinucleotide.

48. The method of claim 47, wherein the poly G nucleic acid is selected from the group consisting of SEQ ID NOs: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

49. The method of claim 1, wherein the nucleic acid is a synthetic nucleic acid.

50. The method of claim 9, wherein the nucleic acid is administered on a routine schedule.

- 66 -

51. The method of claim 1, wherein the angiogenesis is associated with a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular
5 glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars.

52. The method of claim 1, wherein the nucleic acid is not an antisense molecule.

53. A pharmaceutical composition comprising an amount of at least one antiangiogenic nucleic acid molecule effective to inhibit angiogenesis and a pharmaceutically acceptable carrier.

54. The pharmaceutical composition of claim 53, wherein the at least one antiangiogenic nucleic acid molecule comprises at least one sequence set forth as SEQ ID NOs: 1-1093.

55. The pharmaceutical composition of claim 53, wherein two or more antiangiogenic nucleic acid molecules are administered.

56. The pharmaceutical composition of claim 53, further comprising at least one non-nucleic acid angiogenesis inhibitor molecule.

57. The pharmaceutical composition of claim 53, wherein the antiangiogenic nucleic acid
25 molecule has a modified backbone.

58. The pharmaceutical composition of claim 57, wherein the modified backbone is a phosphate modified backbone.

59. The pharmaceutical composition of claim 58, wherein the phosphate modified backbone is a phosphorothioate modified backbone.

60. The pharmaceutical composition of claim 53, further comprising an anticancer agent.

- 67 -

61. The pharmaceutical composition of claim 53, wherein the nucleic acid is a CpG nucleic acid.

5 62. The pharmaceutical composition of claim 53, wherein the nucleic acid is a T-rich nucleic acid.

63. The pharmaceutical composition of claim 53, wherein the nucleic acid is a poly G nucleic acid.

10

64. The pharmaceutical composition of claim 53, wherein the nucleic acid is isolated.

65. The pharmaceutical composition of claim 53, wherein the nucleic acid is not an antisense molecule.

15

66. A kit comprising
a first container housing at least one antiangiogenic nucleic acid molecule, and
instructions for administering the antiangiogenic nucleic acid to a subject having a
condition characterized by unwanted angiogenesis.

20

67. The kit of claim 66, wherein the antiangiogenic nucleic acid has a modified backbone.

68. The kit of claim 67, wherein the modified backbone is a phosphate modified backbone.

25

69. The kit of claim 67, wherein the phosphate modified backbone is a phosphorothioate modified backbone.

70. The kit of claim 65, further comprising a second container housing at least one non-nucleic acid antiangiogenic agent.

30

71. The kit of claim 65, further comprising a second container housing at least one anticancer agent.

- 68 -

72. The kit of claim 69, further comprising a third container housing at least one anticancer agent.

5 73. The kit of claim 65, wherein the nucleic acid is not an antisense molecule.

74. The kit of claim 65, wherein the instructions relate to administering the antiangiogenic nucleic acid to a subject having a condition selected from the group consisting of rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, macular degeneration,
10 corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma, and hypertrophic scars.




Figure 1

- 1 -

SEQUENCE LISTING

<110> Coley Pharmaceutical Group, Inc.

<120> Inhibition of Angiogenesis by Nucleic Acids

<130> C1037/7025WO (HCL/MAT)

<150> US 60/255,534

<151> 2000-12-14

<160> 1093

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1

tctcccagcg tgcgcat

18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 2

ataatccagc ttgaaccaag

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 3

ataatcgacg ttcaagcaag

20

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 4

taccgcgtgc gaccctct

18

- 2 -

<210> 5
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 5
ggggagggt

9

<210> 6
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 6
ggggagggg

9

<210> 7
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 7
ggtgaggtg

9

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 8
tccatgtngt tcctgatgct

20

<210> 9
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (11)...(11)
<223> m5c

<223> Synthetic Sequence

- 3 -

<400> 9
gctaccttag ngtga 15

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 10
tccatgangt tctgatgct 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (13)...(13)
<223> m5c

<223> Synthetic Sequence

<400> 11
tccatgacgt tcntgatgct 20

<210> 12
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 12
gctagangtt agtgt 15

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 13
agctccatgg tgctcactg 19

<210> 14
<211> 20

- 4 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 14
ccacgtcgac cctcaggcga 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 15
gcacatcgtc ccgcagccga 20

<210> 16
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 16
gtcactcgtg gtacctcga 19

<210> 17
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 17
gttgataca ggccagactt tgttg 25

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 18
gattcaactt gcgctcatct taggc 25

<210> 19
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 19
accatggacg aactgtttcc cctc 24

<210> 20
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 20
accatggacg agctgtttcc cctc 24

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 21
accatggacg acctgtttcc cctc 24

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 22
accatggacg tactgtttcc cctc 24

<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 23
accatggacg gtctgtttcc cctc 24

<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 24
accatggacg ttctgtttcc cctc 24

<210> 25
<211> 25
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 25
ccactcacat ctgctgctcc acaag 25

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 26
actttcdata gtccctttgg tccag 25

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 27
tccatgagct tcctgagtct 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (9)...(9)
<223> I

<221> modified_base
<222> (11)...(11)
<223> I

<221> modified_base
<222> (15)...(15)
<223> I

<400> 28
gaggaaggng nggangacgt 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 7 -

<221> modified_base
<222> (7)...(7)
<223> I

<221> modified_base
<222> (13)...(13)
<223> I

<221> modified_base
<222> (18)...(18)
<223> I

<400> 29
gtgaatncgt tcncgggnct 20

<210> 30
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 30
aaaaaa 6

<210> 31
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 31
cccccc 6

<210> 32
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 32
ctgtca 6

<210> 33
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 33
tcgtag 6

<210> 34
<211> 6

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 34
tcgtgg 6

<210> 35
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 35
cgtcgt 6

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 36
tccatgtcgg tcctgagtct 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 37
tccatgccgg tcctgagtct 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 38
tccatgacgg tcctgagtct 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 39
tccatgacgg tcctgagtct 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 40
tccatgtcga tcctgagtct 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 41
tccatgtcgc tcctgagtct 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 42
tccatgtcgt tcctgagtct 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 43
tccatgacgt tcctgagtct 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 44
tccataacgt tcctgagtct 20

<210> 45
<211> 20
<212> DNA

- 10 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 45
tccatgacgt ccctgagtct 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 46
tccatcacgt gcctgagtct 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 47
tccatgctgg tcctgagtct 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<221> modified base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 48
tccatgtngg tcctgagtct 20

<210> 49
<211> 39
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 49
ccgcttcctc cagatgagct catgggtttc tccaccaag 39

<210> 50
<211> 39
<212> DNA
<213> Artificial Sequence

- 11 -

<220>
<223> Synthetic Sequence

<400> 50
cttgggtggag aaacccatga gctcatctgg aggaagcgg 39

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 51
ccccaaaggg atgagaagtt 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 52
agatagcaaa tcggtgacg 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 53
ggttcacgtg ctcattggctg 20

<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 54
tctcccagcg tgcgccat 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 55
tctcccagcg tgcgccat 18

- 12 -

<210> 56
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 56
taccgcgtgc gaccctct 18

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 57
ataatccagc ttgaaccaag 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 58
ataatcgacg ttcaagcaag 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 59
tccatgattt tcctgatttt 20

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 60
ttgttttttt gtttttttgt tttt 24

<210> 61
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

- 13 -

<223> Synthetic Sequence

<400> 61
ttttttttgt tttttgttt tt 22

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 62
tgctgctttt gtgcttttgt gctt 24

<210> 63
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 63
tgctgcttgt gcttttgtgc tt 22

<210> 64
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 64
gcattcatca ggcgggcaag aat 23

<210> 65
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 65
taccgagctt cgacgagatt tca 23

<210> 66
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 66
gcatgacgtt gagct 15

<210> 67

- 14 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 67
cacgttgagg ggcac 15

<210> 68
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 68
ctgctgagac tggag 15

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 69
tccatgacgt tcctgacgtt 20

<210> 70
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 70
gcatgagctt gagctga 17

<210> 71
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 71
tcagcgtgcg cc 12

<210> 72
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 15 -

<400> 72
atgacgttcc tgacgtt 17

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 73
ttttgggggtt ttggggtttt 20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 74
tctaggcttt ttaggcttcc 20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 75
tgcatTTTTT aggccacccat 20

<210> 76
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 76
tctcccagcg tgcgtgcgcc at 22

<210> 77
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 77
tctcccagcg ggcgcacat 17

<210> 78
<211> 18

- 16 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 78
tctcccagcg agcgccat

18

<210> 79
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 79
tctcccagcg cgcgccat

18

<210> 80
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 80
gggggtgacgt tcagggggg

19

<210> 81
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 81
gggggtccagc gtgcgccatg gggg

24

<210> 82
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 82
gggggtgtcgt tcagggggg

19

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 83
tccatgtcgt tcctgtcgtt 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 84
tccatagcgt tcctagcgtt 20

<210> 85
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 85
tcgtcgctgt ctccgcttct t 21

<210> 86
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 86
gcatgacgtt gagct 15

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 87
tctcccagcg tgcgcatat 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<221> modified_base
<222> (17)...(17)
<223> m5c

- 18 -

<223> Synthetic Sequence

<400> 88
tccatgangt tcctgangtt 20

<210> 89
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 89
gcatgangtt gagct 15

<210> 90
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 90
tccagcgtgc gccata 16

<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 91
tctcccagcg tgcgccat 18

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 92
tccatgagct tcctgagtct 20

<210> 93
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 93
gcatgtcgtt gagct 15

<210> 94
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 94
tcctgacgtt cctgacgtt 19

<210> 95
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 95
gcatgatgtt gagct 15

<210> 96
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 96
gcatttcgag gagct 15

<210> 97
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 97
gcatgtagct gagct 15

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 98
tccaggacgt tcctagttct 20

<210> 99
<211> 20
<212> DNA

- 20 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 99

tccaggagct tcctagttct

20

<210> 100

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 100

tccaggatgt tcctagttct

20

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 101

tccagtctag gcctagttct

20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 102

tccagttcga gcctagttct

20

<210> 103

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 103

gcatggcggtt gagct

15

<210> 104

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 104

- 21 -

gcatagcggtt gagct

15

<210> 105
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 105
gcattgcggtt gagct

15

<210> 106
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 106
gcttgcggttg cgttt

15

<210> 107
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 107
tctcccagcg ttgcgccata t

21

<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 108
tctcccagcg tgcggttat

20

<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 109
tctccctgcg tgcgccatat

20

<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 110
tctgcgtgcg tgcgccatat 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 111
tctcctagcg tgcgccatat 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 112
tctcccagcg tgcgcctttt 20

<210> 113
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> misc_difference
<222> (5)...(5)
<223> n is a or g or c or t/u

<221> misc_difference
<222> (6)...(6)
<223> d is a or g or t/u; not c

<221> misc_difference
<222> (9)...(10)
<223> h is a or c or t/u; not g

<400> 113
gctandcghh agc 13

<210> 114
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 114

tcctgacggtt ccc

13

<210> 115
<211> 13
<212> DNA
<213> Artificial Sequence

<220> .
<223> Synthetic Sequence

<400> 115
ggaagacggtt aga

13

<210> 116
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 116
tcctgacggtt aga

13

<210> 117
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 117
tcagaccagc tggtcgggtg ttcttga

27

<210> 118
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 118
tcaggaacac ccgaccagct ggtctga

27

<210> 119
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 119
gctagtcgat agc

13

<210> 120
<211> 13
<212> DNA
<213> Artificial Sequence

- 24 -

<220>
<223> Synthetic Sequence

<400> 120
gctagtcgct agc 13

<210> 121
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 121
gcttgacgct tagc 14

<210> 122
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 122
gcttgacggt tagc 14

<210> 123
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 123
gcttgacgct aagc 14

<210> 124
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 124
gctagacggt tagc 14

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 125
tccatgacat tcctgatgct 20

- 25 -

<210> 126
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 126
gctagacgtc tagc

14

<210> 127
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 127
ggctatgtcg ttcctagcc

19

<210> 128
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 128
ggctatgtcg atcctagcc

19

<210> 129
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 129
ctcatgggtt tctccaccaa g

21

<210> 130
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 130
cttggtggag aaacccatga g

21

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 131
tccatgacgt tcctagttct 20

<210> 132
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 132
ccgcttcctc cagatgagct catg 24

<210> 133
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 133
catgagctca tctggaggaa gcgg 24

<210> 134
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 134
ccagatgagc tcatgggttt ctcc 24

<210> 135
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 135
ggagaaaccc atgagctcat ctgg 24

<210> 136
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 136
agcatcagga acgacatgga 20

- 27 -

<210> 137
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 137
tccatgacgt tcctgacgtt 20

<210> 138
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 138
gcgcgcgcgc gcgcgcgcgc 19

<210> 139
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 139
ccggcgggcc ggccggccgg 20

<210> 140
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 140
ttccaatcag cccacccgc totggcccca ccctcaccct cca 43

<210> 141
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 141
tggagggtga ggggtggggcc agâgcgggtg gggctgattg gaa 43

<210> 142
<211> 27
<212> DNA
<213> Artificial Sequence

<220>

- 28 -

<223> Synthetic Sequence

<400> 142

tcaaattgtgg gattttccca tgagtct

27

<210> 143

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 143

agactcatgg gaaaatccca catttga

27

<210> 144

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 144

tgccaagtgc tgagtcacta ataaaga

27

<210> 145

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 145

tctttattag tgactcagca cttggca

27

<210> 146

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 146

tgcaggaagt ccgggttttc cccaaccccc c

31

<210> 147

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 147

gggggggttg ggaaaaccog gacttctgc a

31

<210> 148

- 29 -

<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 148
ggggactttc cgctggggac ttccagggg gactttcc

38

<210> 149
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 149
tccatgacgt tcctctccat gacgttcctc tccatgacgt tcctc

45

<210> 150
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 150
gaggaacgtc atggagagga acgtcatgga gaggaacgtc atgga

45

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 151
ataatagagc ttcaagcaag

20

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 152
tccatgacgt tcctgacgtt

20

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 153
tccatgacgt tcctgacgtt 20

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 154
tccaggactt tcctcaggtt 20

<210> 155
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 155
tcttgcatg ctaaaggacg tcacattgca caatcttaat aaggt 45

<210> 156
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 156
accttattaa gattgtgcaa tgtgacgtcc tttagcatcg caaga 45

<210> 157
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 157
tcctgacgtt cctggcggtc ctgtcgct 28

<210> 158
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 158
tcctgtcgct cctgtcgct 19

<210> 159
<211> 15

- 31 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 159
tcctgacgtt gaagt 15

<210> 160
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 160
tcctgtcgtt gaagt 15

<210> 161
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 161
tcctggcgtt gaagt 15

<210> 162
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 162
tcctgccgtt gaagt 15

<210> 163
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 163
tccttacgtt gaagt 15

<210> 164
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 32 -

<400> 164
tcctaacggt gaagt 15

<210> 165
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 165
tcctcacggt gaagt 15

<210> 166
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 166
tcctgacgat gaagt 15

<210> 167
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 167
tcctgacgct gaagt 15

<210> 168
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 168
tcctgacggt gaagt 15

<210> 169
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 169
tcctgacgta gaagt 15

<210> 170
<211> 15
<212> DNA

- 33 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 170

tcctgacgtc gaagt

15

<210> 171

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 171

tcctgacgtg gaagt

15

<210> 172

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 172

tcctgagctt gaagt

15

<210> 173

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 173

gggggacgtt ggggg

15

<210> 174

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 174

tcctgacgtt ccttc

15

<210> 175

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 175

- 34 -
22

tctcccagcg agcgagcgcc at

<210> 176
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 176
tcttgacgtt cccctggcgg tcccctgtcg ct

32

<210> 177
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 177
tcctgtcgct cctgtcgctc ctgtcgct

28

<210> 178
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 178
tcctggcggg gaagt

15

<210> 179
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 179
tcctgangtt gaagt

15

<210> 180
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (3)...(3)
<223> m5c

<223> Synthetic Sequence

<400> 180
tcntgacggt gaagt 15

<210> 181
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 181
tcctagcggt gaagt 15

<210> 182
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 182
tccagacggt gaagt 15

<210> 183
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 183
tcctgacggg gaagt 15

<210> 184
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 184
tcctggcggt gaagt 15

<210> 185
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 185
ggctccgggg agggatttt tgtctat 27

<210> 186
<211> 27

- 36 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 186
atagacaaaa attccctccc cggagcc 27

<210> 187
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 187
tccatgagct tccttgagtc t 21

<210> 188
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 188
tcgtcgctgt ctccgcttct t 21

<210> 189
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 189
tcgtcgctgt ctccgcttct t 21

<210> 190
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 190
tcgagacatt gcacaatcat ctg 23

<210> 191
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 191
cagattgtgc aatgtctcga 20

<210> 192
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 192
tccatgtcgt tcctgatgcg 20

<210> 193
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 193
gcgatgtcgt tcctgatgct 20

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 194
gcgatgtcgt tcctgatgcg 20

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 195
tccatgtcgt tccgcgcgcg 20

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 196
tccatgtcgt tcctgccgct 20

<210> 197
<211> 20
<212> DNA

- 38 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 197
tccatgtcgt tcctgtagct 20

<210> 198
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 198
gcggcgggcg gcgcgcgccc 20

<210> 199
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 199
atcaggaacg tcatgggaag c 21

<210> 200
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 200
tccatgagct tcctgagtct 20

<210> 201
<211> 8
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 201
tcaacggt 8

<210> 202
<211> 8
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 202

- 39 -

8

tcaagctt

<210> 203
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 203
tcctgtcgtt cctgtcgtt

19

<210> 204
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 204
tccatgtcgt tttgtcgtt

20

<210> 205
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 205
tcctgtcgtt cctgtcgtt

20

<210> 206
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 206
tcctgtcgtt tcctgtcgtt

20

<210> 207
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 207
tccattccat gacgttcctg atgcttcca

29

- 40 -

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 208
tcctgtcggtt ttttgtcggtt 20

<210> 209
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 209
tcgtcgctgt ctccgcttct t 21

<210> 210
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 210
tcgtcgctgt ctgcccttct t 21

<210> 211
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 211
tcgtcgctgt tgcgtttct t 21

<210> 212
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 212
tcctgtcggtt cctgtcggtt gaacgacagg 30

<210> 213
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

- 41 -

<223> Synthetic Sequence

<400> 213

tcctgtcgtt cctgtcgttt caacgtcagg aacgacagga

40

<210> 214

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 214

ggggtctgtc gttttggggg g

21

<210> 215

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 215

ggggtctgtg cttttggggg g

21

<210> 216

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 216

tccggccggt gaagt

15

<210> 217

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 217

tccggacggt gaagt

15

<210> 218

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 218

tcccgccggt gaagt

15

<210> 219

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 219
tccagacggt gaagt 15

<210> 220
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 220
tcccagacggt gaagt 15

<210> 221
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 221
tccagagctt gaagt 15

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<221> modified_base
<222> (17)...(17)
<223> m5c

<223> Synthetic Sequence

<400> 222
tccatgtngt tcctgtngtt 20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 223
tccatgacgt tcctgacgtt 20

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 224
ggggttgacg ttttgggggg 20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 225
tccaggactt ctctcaggtt 20

<210> 226
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 226
tttttttttt tttttttttt 20

<210> 227
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 227
tccatgccgt tcctgccgtt 20

<210> 228
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 228
tccatggcgg gcctggcggg 20

<210> 229
<211> 20
<212> DNA
<213> Artificial Sequence

- 44 -

<220>
<223> Synthetic Sequence

<400> 229
tccatgacgt tcctgccgtt 20

<210> 230
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 230
tccatgacgt tcctggcggg 20

<210> 231
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 231
tccatgacgt tcctgcgttt 20

<210> 232
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 232
tccatgacgg tcctgacggt 20

<210> 233
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 233
tccatgctg cgtgcgtttt 20

<210> 234
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 234
tccatgcgtt gcgttgcgtt 20

- 45 -

<210> 235
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 235
tccattccat tctaggcctg agtcttccat 30

<210> 236
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 236
tccatagcgt tcctagcggt 20

<210> 237
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 237
tccatgtcgt tcctgtcggt 20

<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 238
tccatagcga tcctagcgat 20

<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 239
tccattgcgt tccttgcgtt 20

<210> 240
<211> 20

- 46 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 240
tccatagcgg tcctagcgg 20

<210> 241
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 241
tccatgattt tcctgcagtt cctgatttt 29

<210> 242
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 242
tccatgacgt tcctgcagtt cctgacgtt 29

<210> 243
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 243
ggcggcggcg ggcggcggcg 20

<210> 244
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 244
tccacgacgt tticgacgtt 20

<210> 245
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 47 -

<400> 245
tcgtcggtgt cgttgcgtt 20

<210> 246
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 246
tcgtcgtttt gtcgttttgcgtt 24

<210> 247
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 247
tcgtcggtgt cgttttgcgt tt 22

<210> 248
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 248
gcgtgcgttg tcgttgcgt t 21

<210> 249
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (6)...(6)
<223> m5c

<221> modified_base
<222> (10)...(10)
<223> m5c

<221> modified_base
<222> (15)...(15)
<223> m5c

<400> 249

cnggcnggcg gggcncgcg

19

<210> 250
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 250

gcggcgggcg gcgcgcgccc

20

<210> 251
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified base
<222> (3)...(3)
<223> I

<221> modified base
<222> (8)...(8)
<223> I

<221> modified base
<222> (14)...(14)
<223> I

<400> 251

agncccgnga acgnattcac

20

<210> 252
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 252

tgtcgtttgt cgtttgtcgt t

21

<210> 253
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 253

tgtcgttgtc gttgtcgttg tcgtt

25

<210> 254
<211> 25
<212> DNA

- 49 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 254
tgtcgttgtc gttgtcgttg tcgtt 25

<210> 255
<211> 14
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 255
tcgtcgtcgt cggtt 14

<210> 256
<211> 13
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 256
tgtcgttgtc gtt 13

<210> 257
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 257
cccccccccc ccccccccccc 20

<210> 258
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 258
tctagcgttt ttagcgttcc 20

<210> 259
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 259

- 50 -

tgcaccccc aggcacccat

20

<210> 260
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 260
tcgtcgtcgt cgtcgtcgtc gtt

23

<210> 261
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 261
tcgtcgttgt cgttgcgtt

20

<210> 262
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 262
tcgtcgtttt gtcgttttgcgtt

24

<210> 263
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 263
tcgtcgttgcgttgcgttgcgtt

22

<210> 264
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 264
ggggaggagg gaacttctta aaattccccc agaattgtt

39

<210> 265
<211> 39
<212> DNA
<213> Artificial Sequence

- 51 -

<220>
<223> Synthetic Sequence

<400> 265
aaacattctg ggggaatttt aagaagttcc tccctcccc 39

<210> 266
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 266
atgtttactt cttaaaattc ccccagaatg ttt 33

<210> 267
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 267
aaacattctg ggggaatttt aagaagtaaa cat 33

<210> 268
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 268
atgtttacta gacaaaattc ccccagaatg ttt 33

<210> 269
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 269
aaacattctg ggggaatttt gtctagtaaa cat 33

<210> 270
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 270
aaaattgacg ttttaaaaaa 20

- 52 -

<210> 271
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 271
ccccttgacg ttttcccccc 20

<210> 272
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 272
ttttcgttgt ttttgctgtt 20

<210> 273
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 273
tcgtcgtttt gtcgttttgt cgtt 24

<210> 274
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 274
ctgcagcctg ggac 14

<210> 275
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 275
accgcgtgta attatagtaa aaccc 25

<210> 276
<211> 21
<212> DNA
<213> Artificial Sequence

- 53 -

<220>
<223> Synthetic Sequence

<400> 276
ggtacctgtg gggacattgt g 21

<210> 277
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 277
agcaccgaac gtgagagg 18

<210> 278
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 278
tccatgccgt tcctgccgtt 20

<210> 279
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 279
tccatgacgg tcctgacggt 20

<210> 280
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 280
tccatgccgg tcctgccggt 20

<210> 281
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 281
tccatgcgcg tcctgcgcggt 20

- 54 -

<210> 282
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 282
ctggtctttc tggttttttt ctgg 24

<210> 283
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 283
tcaggggtgg ggggaacctt 20

<210> 284
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 284
tccatgangt tcctagttct 20

<210> 285
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 285
tccatgatgt tcctagttct 20

<210> 286
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 286
cccgaagtca tttcctctta acctgg 26

<210> 287
<211> 26

- 55 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 287
ccaggttaag aggaaatgac ttcggg 26

<210> 288
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 288
tcctggnggg gaagt 15

<210> 289
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (5)...(5)
<223> m5c

<221> modified_base
<222> (9)...(9)
<223> m5c

<221> modified_base
<222> (12)...(12)
<223> m5c

<221> modified_base
<222> (14)...(14)
<223> m5c

<221> modified_base
<222> (16)...(16)
<223> m5c

<223> Synthetic Sequence

<400> 289
gnggngggng gngngngccc 20

<210> 290
<211> 20

- 56 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 290
tccatgtgct tcctgatgct 20

<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 291
tccatgtcct tcctgatgct 20

<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 292
tccatgtcgt tcctagttct 20

<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 293
tccaagtagt tcctagttct 20

<210> 294
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 294
tccatgtagt tcctagttct 20

<210> 295
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 295
tcccgcgcgt tccgcgcgtt 20

<210> 296
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 296
tcctggcggg cctggcgggt 20

<210> 297
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 297
tcctggaggg gaagt 15

<210> 298
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 298
tcctgggggg gaagt 15

<210> 299
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 299
tcctggtggg gaagt 15

<210> 300
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 300
tcgtcgtttt gtcgttttgc cggt 24

<210> 301
<211> 24
<212> DNA

- 58 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 301

ctggtctttc tggttttttt ctgg 24

<210> 302

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 302

tccatgacgt tcctgacgtt 20

<210> 303

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 303

tccaggactt ctctcaggtt 20

<210> 304

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<221> modified_base

<222> (2)...(2)

<223> m5c

<221> modified_base

<222> (5)...(5)

<223> m5c

<221> modified_base

<222> (13)...(13)

<223> m5c

<221> modified_base

<222> (21)...(21)

<223> m5c

<400> 304

tngtngtttt gtngttttgt ngtt 24

<210> 305

<211> 29

<212> DNA

<213> Artificial Sequence

- 59 -

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 305
tcgtcgtttt gtcgttttgt cgttttttt 29

<210> 306
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 306
gctatgacgt tccaagg 18

<210> 307
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 307
tcaacgtt 8

<210> 308
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 308
tccaggactt tcctcaggtt 20

<210> 309
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 309
ctctctgtag gcccgcttgg 20

<210> 310
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 60 -

<223> Synthetic Sequence

<400> 310
ctttccgttg gacctctggg 20

<210> 311
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 311
gtccgggcca ggccaaagtc 20

<210> 312
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 312
gtgcgcgcga gcccgaaatc 20

<210> 313
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> I

<221> modified_base
<222> (17)...(17)
<223> I

<223> Synthetic Sequence

<400> 313
tccatgangt tcctgangtt 20

<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 314
aatagtcgcc ataacaaaac 20

<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence

- 61 -

<220>
<223> Synthetic Sequence

<400> 315
aatagtcgcc atggcggggc 20

<210> 316
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 316
tttttccatg tggttcctga tgcttttt 28

<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 317
tcctgtcggt gaagtttttt 20

<210> 318
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 318
gctagcttta gagctttaga gctt 24

<210> 319
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 319
tgctgcttcc cccccccccc 20

<210> 320
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 62 -

<223> Synthetic Sequence

<400> 320
tcgacgttcc cccccccccc 20

<210> 321
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 321
tcgtcgttcc cccccccccc 20

<210> 322
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 322
tcgtcgttcc cccccccccc 20

<210> 323
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 323
tcgccgttcc cccccccccc 20

<210> 324
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 324
tcgtcgatcc cccccccccc 20

<210> 325
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 325
tcctgacgtt gaagt 15

<210> 326

- 63 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 326
tcctgccgtt gaagt 15

<210> 327
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 327
tcctgacggt gaagt 15

<210> 328
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 328
tcctgagctt gaagt 15

<210> 329
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 329
tcctggcggg gaagt 15

<210> 330
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 330
aaaatctgtg cttttaaaaa a 21

<210> 331
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 331
gatccagtca cagtgcctg gcagaatctg gat 33

<210> 332
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 332
gatccagatt ctgccaggtc actgtgactg gat 33

<210> 333
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 333
gatccagtca cagtgactca gcagaatctg gat 33

<210> 334
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 334
gatccagatt ctgctgagtc actgtgactg gat 33

<210> 335
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (16)...(16)
<223> m5c

<223> Synthetic Sequence

<400> 335
tcgtcgttcc ccccccncccc 20

<210> 336
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

- 65 -

<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 336
tngtngttcc cccccccccc 20

<210> 337
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 337
tngtcgttcc cccccccccc 20

<210> 338
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 338
tcgtngttcc cccccccccc 20

<210> 339
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 339
tcgtcgctcc cccccccccc 20

<210> 340
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 340
tcgtcggtcc cccccccccc 20

<210> 341
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 341
tcggcggttcc cccccccccc 20

<210> 342
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 342
ggccttttcc cccccccccc 20

<210> 343
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 343
tcgtcgtttt gacgttttgc cggt 24

<210> 344
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 344
tcgtcgtttt gacgttttga cggt 24

<210> 345
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 345
ccgtcggttcc cccccccccc 20

<210> 346
<211> 20
<212> DNA
<213> Artificial Sequence

- 67 -

<220>
<223> Synthetic Sequence

<400> 346
gcgtcgttcc cccccccccc 20

<210> 347
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 347
tcgtcattcc cccccccccc 20

<210> 348
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 348
acgtcgttcc cccccccccc 20

<210> 349
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 349
ctgtcgttcc cccccccccc 20

<210> 350
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 350
tttttcgtcg ttcccccccc cccc 24

<210> 351
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature

- 68 -

<222> (18)...(20)
<223> Biotin moiety attached at 3' end of sequence.

<223> Synthetic Sequence

<400> 351
tcgtcgttcc cccccccccc 20

<210> 352
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (22)...(24)
<223> Biotin moiety attached at 3' end of sequence.

<223> Synthetic Sequence

<400> 352
tcgtcgtttt gtcgttttgt cgtt 24

<210> 353
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 353
tccagttcct tcctcagtct 20

<210> 354
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 354
tngtcgtttt gtcgttttgt cgtt 24

<210> 355
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 355
tcctggaggg gaagt 15

<210> 356

- 69 -

<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 356
tcctgaaaag gaagt 15

<210> 357
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 357
tcgtcgttcc cccccc 17

<210> 358
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (2)...(2)
<223> m5c

<221> modified_base
<222> (5)...(5)
<223> m5c

<221> modified_base
<222> (13)...(13)
<223> m5c

<221> modified_base
<222> (21)...(21)
<223> m5c

<400> 358
tngtngtttt gtngttttgt ngtt 24

<210> 359
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 359
ggggtcaagc ttgagggggg 20

<210> 360
<211> 20

- 70 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 360
tgctgcttcc cccccccccc 20

<210> 361
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 361
tcgtcgtcgt cggt 14

<210> 362
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 362
tcgtcgtcgt cggt 14

<210> 363
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 363
tcgtcgtcgt cggt 14

<210> 364
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 364
tcaacggtga 10

<210> 365
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 365
tcaacggtt 8

<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 366
atagttttcc atttttttac 20

<210> 367
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 367
aatagtcgcc atcgcgcgac 20

<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 368
aatagtcgcc atccccgggac 20

<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 369
aatagtcgcc atcccccccc 20

<210> 370
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 370
tgctgctttt gtgcttttgt gctt 24

<210> 371
<211> 24
<212> DNA

- 72 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 371

ctgtgctttc tgtgtttttc tgtg 24

<210> 372

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 372

ctaactctttc taattttttt ctaa 24

<210> 373

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 373

tcgtcgttgg tgcgttggg gtcgtt 26

<210> 374

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 374

tcgtcgttgg ttgtcgtttt gggt 24

<210> 375

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 375

accatggacg agctgtttcc cctc 24

<210> 376

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 376

tcgtcgtttt gcgtgcgttt

20

<210> 377
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

ctgtaagtga gcttggagag

20

<210> 378
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

gagaacgctg gaccttcc

18

<210> 379
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

cgggcgactc agtctatcgg

20

<210> 380
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

gttctcagat aaagcggaac cagcaacaga cacagaa

37

<210> 381
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

ttctgtgtct gttgctggtt ccgctttatc tgagaac

37

<210> 382
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 382
cagacacaga agccccgatag acg 23

<210> 383
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 383
agacagacac gaaacgaccg 20

<210> 384
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 384
gtctgtccca tgatctcgaa 20

<210> 385
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 385
gctggccagc ttacctcccg 20

<210> 386
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 386
ggggcctcta tacaacctgg g 21

<210> 387
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 387
gggggtccctg agactgcc 18

- 75 -

<210> 388
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 388
gagaacgctg gaccttccat 20

<210> 389
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 389
tccatgtcgg tcctgatgct 20

<210> 390
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 390
ctcttgcgac ctggaaggta 20

<210> 391
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 391
aggtacagcc aggactacga 20

<210> 392
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 392
accatggacg acctgtttcc cctc 24

<210> 393
<211> 24
<212> DNA
<213> Artificial Sequence

- 76 -

<220>
<223> Synthetic Sequence

<400> 393
accatggatt acctttttcc cctt 24

<210> 394
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 394
atggaagggtc cagcgttctc 20

<210> 395
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 395
agcatcagga ccgacatgga 20

<210> 396
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 396
ctctccaagc tcacttacag 20

<210> 397
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 397
tccttgagac tgccccacct t 21

<210> 398
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 398
gccaccaaaa cttgtccatg 20

- 77 -

<210> 399
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 399
gtccatggcg tgcgggatga 20

<210> 400
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 400
cctctataca acctgggac 19

<210> 401
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 401
cgggcgactc agtctatcgg 20

<210> 402
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 402
gcgctaccgg tagcctgagt 20

<210> 403
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 403
cgactgccga acaggatatc ggtgatcagc actgg 35

<210> 404
<211> 35
<212> DNA
<213> Artificial Sequence

<220>

- 78 -

<223> Synthetic Sequence

<400> 404

ccagtgctga tcaccgatat cctgttcggc agtcg

35

<210> 405

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 405

ccaggttgta tagaggc

17

<210> 406

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 406

tctcccagcg tacgccat

18

<210> 407

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 407

tctcccagcg tgcgtttt

18

<210> 408

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 408

tctcccagcg tgcgccat

18

<210> 409

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 409

tctcccgtag tgcgccat

18

<210> 410

- 79 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 410
ataatcgtcg ttcaagcaag 20

<210> 411
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 411
tcgtcgtttt gtcgttttgt cgt 23

<210> 412
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 412
tcgtcgtttt gtcgttttgt cgtt 24

<210> 413
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 413
tcgtcgtttt gtcgttttgt cgtt 24

<210> 414
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (3)...(3)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (8)...(8)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (11)...(11)
<223> n is a or c or g or t/u

- 80 -

<221> misc_difference
<222> (16)...(16)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (19)...(19)
<223> n is a or c or g or t/u

<221> misc_difference
<222> (24)...(24)
<223> n is a or c or g or t/u

<223> Synthetic Sequence

<400> 414
tcttcgtntt ntcgtnttnt cgtn 24

<210> 415
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 415
tctcccagcg tcgcat 17

<210> 416
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 416
tctcccatcg tcgcat 17

<210> 417
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 417
ataatcgtgc gttcaagaaa g 21

<210> 418
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 418
ataatcgacg ttcccccccc 20

- 81 -

<210> 419
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 419
tctatcgacg ttcaagcaag 20

<210> 420
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 420
tcctgacggg gagt 14

<210> 421
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 421
tccatgacgt tcctgatcc 19

<210> 422
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 422
tccatgacgt tcctgatcc 19

<210> 423
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 423
tccatgacgt tcctgatcc 19

<210> 424
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 424
tcctggcgtg gaagt 15

<210> 425
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 425
tccatgacgt tcctgatcc 19

<210> 426
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 426
tcgtcgctgt tgctgtttct t 21

<210> 427
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 427
agcagcttta gagctttaga gctt 24

<210> 428
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 428
cccccccccc ccccccccc cccc 24

<210> 429
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 429
tcgtcgtttt gtcgttttgc cgttttgcg tt 32

<210> 430

- 83 -

<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 430
tcgtcgtttt ttgtcgtttt ttgtcgtt 28

<210> 431
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 431
tcgtcgtttt tttttttttt 20

<210> 432
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 432
tttttcaacg ttgatttttt 20

<210> 433
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 433
tttttttttt tttttttttt tttt 24

<210> 434
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 434
ggggtcgtcg ttttgggggg 20

<210> 435
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 84 -

<400> 435
tcgtcgtttt gtcgttttgg gggg 24
<210> 436
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 436
tcgtcgctgt ctccgcttct tcttgcc 27
<210> 437
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 437
tcgtcgctgt ctccg 15
<210> 438
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 438
ctgtaagtga gcttgagag 20
<210> 439
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 439
gagaacgctg gaccttccat 20
<210> 440
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence

<400> 440
ccagggttga tagaggc 17
<210> 441
<211> 17

- 85 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 441
gctagacgtt agcgtga 17

<210> 442
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 442
ggagctcttc gaacgccata 20

<210> 443
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 443
tctccatgat ggttttatcg 20

<210> 444
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 444
aaggtggggc agtctcaggg a 21

<210> 445
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 445
atcggaggac tggcgcgccg 20

<210> 446
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 446
ttaggacaag gtctagggtg 20

<210> 447
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 447
accacaacga gaggaacgca 20

<210> 448
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 448
ggcagtgcag gctcaccggg 20

<210> 449
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 449
gaaccttcca tgctgtt 17

<210> 450
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 450
gctagacgtt agcgtga 17

<210> 451
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 451
gcttggaggg cctgtaagtg 20

<210> 452
<211> 12
<212> DNA

- 87 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 452
gtagccttcc ta 12

<210> 453
<211> 14
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 453
cggtagcctt ccta 14

<210> 454
<211> 16
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 454
cacggtagcc ttccta 16

<210> 455
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 455
agcacggtag ccttccta 18

<210> 456
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 456
gaacgctgga ccttcctat 18

<210> 457
<211> 10
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 457

- 88 -

gaccttccat

10

<210> 458
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 458
tggaccttcc at

12

<210> 459
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 459
gctggacctt ccat

14

<210> 460
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 460
acgctggacc ttccat

16

<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 461
taagctctgt caacgccagg

20

<210> 462
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 462
gagaacgctg gaccttccat gt

22

<210> 463
<211> 20
<212> DNA
<213> Artificial Sequence

- 89 -

<220>
<223> Synthetic Sequence

<400> 463
tccatgtcgg tcctgatgct 20

<210> 464
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 464
ttcatgcctt gcaaaatggc g 21

<210> 465
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 465
tgctagctgt gcctgtacct 20

<210> 466
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 466
agcatcagga ccgacatgga 20

<210> 467
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 467
gaccttccat gtcggtcctg at 22

<210> 468
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 468
acaaccacga gaacgggaac 20

- 90 -

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 469
gaacctttcca tgctgttccg 20

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 470
caatcaatct gaggagaccc 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 471
tcagctctgg tactttttca 20

<210> 472
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 472
tggttacggt ctgtcccatg 20

<210> 473
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 473
gtctatcgga ggactggcgc 20

<210> 474
<211> 20
<212> DNA
<213> Artificial Sequence

- 91 -

<220>
<223> Synthetic Sequence

<400> 474
cattttacgg gcgggcgggc 20

<210> 475
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 475
gaggggacca ttttacgggc 20

<210> 476
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 476
tgtccagccg aggggaccat 20

<210> 477
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 477
cgggccttacg gcggatgctg 20

<210> 478
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 478
tggaccttct atgtcgtcc 20

<210> 479
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 479
tgtcccatgt ttttagaagc 20

- 92 -

<210> 480
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 480
gtggttacgg tcgtgcccat 20

<210> 481
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 481
cctccaaatg aaagaccccc 20

<210> 482
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 482
ttgtactctc catgatggtt 20

<210> 483
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 483
ttccatgctg ttccggctgg 20

<210> 484
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 484
gaccttctat gtcggtcctg 20

<210> 485
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 93 -

<223> Synthetic Sequence

<400> 485
gagaccgctc gaccttcgat 20

<210> 486
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 486
ttgccccata ttttagaaac 20

<210> 487
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 487
ttgaaactga ggtgggac 18

<210> 488
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 488
ctatcggagg actggcgcg c 21

<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 489
cttgaggggc ctcccggcgg 20

<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 490
gctgaacctt ccatgctgtt 20

<210> 491

- 94 -

<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 491
tagaaacagc attcttcttt tagggcagca ca 32

<210> 492
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 492
agatggttct cagataaagc ggaa 24

<210> 493
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 493
ttccgcttta tctgagaacc atct 24

<210> 494
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 494
gtcccaggtt gtatagaggc tgc 23

<210> 495
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 495
gcgccagtcc tccgatagac 20

<210> 496
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 95 -

<400> 496
atcggaggac tggcgcgccg 20

<210> 497
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 497
ggtctgtccc atatttttag 20

<210> 498
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 498
tttttcaacg ttgagggggg 20

<210> 499
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 499
tttttcaagc gttgattttt t 21

<210> 500
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 500
ggggtcaacg ttgatttttt 20

<210> 501
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 501
ggggttttca acgttttgag ggggg 25

<210> 502
<211> 20

- 96 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 502
ggttacggtc tgtcccatat 20

<210> 503
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 503
ctgtcccata tttttagaca 20

<210> 504
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 504
accatcctga ggccattcgg 20

<210> 505
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 505
cgtctatcgg gcttctgtgt ctg 23

<210> 506
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 506
ggccatccca cattgaaagt t 21

<210> 507
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 97 -

<400> 507
ccaaatatcg gtggtcaagc ac 22

<210> 508
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 508
gtgcttgacc accgatattt gg 22

<210> 509
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 509
gtgctgatca ccgatatcct gttcgg 26

<210> 510
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 510
ggccaacttt caatgtggga tggcctc 27

<210> 511
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 511
ttccgccgaa tggcctcagg atggtac 27

<210> 512
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 512
tatagtcctt gagactgccc caccttctca acaacc 36

<210> 513
<211> 27
<212> DNA

- 98 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 513
gcagcctcta tacaacctgg gacggga 27

<210> 514
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 514
ctatcgagg actggcgcg cg 22

<210> 515
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 515
tatcgaggga ctggcgcgcc g 21

<210> 516
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 516
gatcgaggga ctggcgcgcc g 21

<210> 517
<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 517
ccgaacagga tatcggtgat cagcac 26

<210> 518
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 518

- 99 -

ttttggggtc aacgttgagg gggg

24

<210> 519
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 519
gggggtcaacg ttgagggggg

20

<210> 520
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 520
cgcgcgcgcg cgcgcgcgcg

20

<210> 521
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 521
ggggcatgac gttcgggggg

20

<210> 522
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 522
ggggcatgac gttcaaaaaa

20

<210> 523
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 523
ggggcatgag cttcgggggg

20

<210> 524
<211> 20
<212> DNA
<213> Artificial Sequence

- 100 -

<220>
<223> Synthetic Sequence

<400> 524
ggggcatgac gttcgggggg 20

<210> 525
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 525
aaaacatgac gttcaaaaaa 20

<210> 526
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 526
aaaacatgac gttcgggggg 20

<210> 527
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 527
ggggcatgac gttcaaaaaa 20

<210> 528
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 528
accatggacg atctgtttcc cctc 24

<210> 529
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 529
gccatggacg aactgtttcc cctc 24

<210> 530
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 530
cccccccccc ccccccccccc 20

<210> 531
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 531
gggggggggg gggggggggg 20

<210> 532
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 532
gctgtaaaat gaatcggccg 20

<210> 533
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 533
ttcgggcgga ctctccatt 20

<210> 534
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 534
tatgccgcgc ccgacttat 20

<210> 535
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 535
ggggtaatcg atcagggggg 20

<210> 536
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 536
tttgagaacg ctggaccttc 20

<210> 537
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 537
gatcgctgat ctaatgctcg 20

<210> 538
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 538
gtcggtcctg atgctgttcc 20

<210> 539
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 539
tcgtcgtcag ttcgctgtcg 20

<210> 540
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 540
ctggaccttc catgtcgg 18

- 103 -

<210> 541
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 541
gctcggtcag cgcgtct

17

<210> 542
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 542
ctggaccttc catgtc

16

<210> 543
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 543
cactgtcctt cgtcga

16

<210> 544
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 544
cgctggacct tccatgtcgg

20

<210> 545
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 545
gctgagctca tgccgtctgc

20

<210> 546
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 104 -

<223> Synthetic Sequence

<400> 546
aacgctggac cttccatgtc 20

<210> 547
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 547
tgcattgccgt acacagctct 20

<210> 548
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 548
ccttccatgt cggctctgat 20

<210> 549
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 549
tactcttcggt atcccttgctg 20

<210> 550
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 550
ttccatgtcg gtcctgat 18

<210> 551
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 551
ctgattgctc tctcgtga 18

<210> 552

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 552
ggcgttattc ctgactcgcc 20

<210> 553
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 553
cctacgttgt atgcgccag ct 22

<210> 554
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 554
ggggtaatcg atgagggggg 20

<210> 555
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 555
ttcgggcgga ctctccatt 20

<210> 556
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 556
tttttttttt tttttttttt 20

<210> 557
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 106 -

<400> 557
gggggttttt ttttggggg 20

<210> 558
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 558
ttttggggg ggggttttt 20

<210> 559
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 559
gggggggggg ggggggggt 19

<210> 560
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 560
aaaaaaaaa aaaaaaaaaa 20

<210> 561
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 561
cccccaaaa aaaaaccccc 20

<210> 562
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 562
aaaaaccccc cccccaaaaa 20

<210> 563
<211> 27

- 107 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 563
tttgaattca ggactggtga ggttgag 27

<210> 564
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 564
tttgaatcct cagcggtctc cagtggc 27

<210> 565
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 565
aattctctat cggggcttct gtgtctgttg ctggttcgcg tttat 45

<210> 566
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 566
ctagataaag cggaaccagc aacagacaca gaagccccga tagag 45

<210> 567
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 567
ttttctagag aggtgcacaa tgctctgg 28

<210> 568
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 568
tttgaattcc gtgtacagaa gcgagaagc 29

<210> 569
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 569
tttgcggccg ctgacttaa cctgagagat a 31

<210> 570
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 570
tttgggcccc cgagagacag agacacttc 29

<210> 571
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 571
tttgggcccc cttctcgctt ctgtacacg 29

<210> 572
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 572
gagaacgctg gaccttccat 20

<210> 573
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 573
tccatgtcgg tcctgatgct 20

<210> 574
<211> 6
<212> DNA

- 109 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 574

ctgtcg 6

<210> 575

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 575

tcgtga 6

<210> 576

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 576

cgtcga 6

<210> 577

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 577

agtgct 6

<210> 578

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 578

ctgtcg 6

<210> 579

<211> 6

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 579

agtgct	6
<210> 580	
<211> 6	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 580	
cgtcga	6
<210> 581	
<211> 6	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 581	
tcgtga	6
<210> 582	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 582	
gagaacgctc cagcttcgat	20
<210> 583	
<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 583	
gctagacgta agcgtga	17
<210> 584	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 584	
gagaacgctc gaccttccat	20
<210> 585	
<211> 21	
<212> DNA	
<213> Artificial Sequence	

- 111 -

<220>
<223> Synthetic Sequence

<400> 585
gagaacgctg gacctatcca t 21

<210> 586
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 586
gctagaggtt agcgtga 17

<210> 587
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 587
gagaacgctg gacttccat 19

<210> 588
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 588
tcacgctaac gtctagc 17

<210> 589
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 589
gctagacgtt agcgtga 17

<210> 590
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 112 -

<223> Synthetic Sequence

<400> 590
atggaaggctc gacggttctc 20

<210> 591
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 591
gagaacgctg gaccttcgat 20

<210> 592
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 592
gagaacgatg gaccttccat 20

<210> 593
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 593
gagaacgctg gatccat 17

<210> 594
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 594
gagaacgctc cagcactgat 20

<210> 595
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 595
tccatgtcgg tcctgctgat 20

<210> 596

- 113 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 596
atgtcctcgg tctgatgct 20

<210> 597
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 597
gagaacgctc caccttccat 20

<210> 598
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 598
gagaacgctg gaccttcgta 20

<210> 599
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 599
atggaaggtc cagcgttctc 20

<210> 600
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 600
tcctga 6

<210> 601
<211> 8
<212> DNA

- 114 -

<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 601
tcaacggtt 8
<210> 602
<211> 6
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 602
aacggtt 6
<210> 603
<211> 8
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 603
aacgttga 8
<210> 604
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 604
tcacgctaac ctctagc 17
<210> 605
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 605
gagaacgctg gaccttgcac 20
<210> 606
<211> 14
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 606

- 115 -

gctggacctt ccat

14

<210> 607
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 607
gagaacgctg gacctcatcc at

22

<210> 608
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 608
gagaacgctg gacgctcatc cat

23

<210> 609
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 609
aacgttgagg ggcat

15

<210> 610
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 610
atgcccctca acgtt

15

<210> 611
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 611
tcaacgttga

10

<210> 612
<211> 14
<212> DNA
<213> Artificial Sequence

- 116 -

<220>
<223> Synthetic Sequence

<400> 612
gctggacctt ccat 14

<210> 613
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 613
caacgtt 7

<210> 614
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 614
acaacgttga 10

<210> 615
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 615
tcacgt 6

<210> 616
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 616
tcaagctt 8

<210> 617
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 617
tcgtca 6

- 117 -

<210> 618
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 618
aggatatac 8

<210> 619
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 619
tagacgtc 8

<210> 620
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 620
gacgtcat 8

<210> 621
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 621
ccatcgat 8

<210> 622
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 622
atcgatgt 8

<210> 623
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 623
atgcatgt 8

<210> 624
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 624
ccatgcat 8

<210> 625
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 625
agcgctga 8

<210> 626
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 626
tcagcgct 8

<210> 627
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 627
ccttcgat 8

<210> 628
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 628
gtgccggggt ctccgggc 18

- 119 -

<210> 629
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 629
gctgtggggc ggctcctg

18

<210> 630
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 630
tcaacggt

8

<210> 631
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 631
tcaacggt

8

<210> 632
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 632
aacgttga

8

<210> 633
<211> 7
<212> DNA
<213> Artificial Sequence

- 120 -

<220>
<223> Synthetic Sequence

<400> 633
tcaacgt 7

<210> 634
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 634
aacgttg 7

<210> 635
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 635
cgacga 6

<210> 636
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 636
tcaacgtt 8

<210> 637
<211> 5
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 637
tcgga 5

<210> 638
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 638
agaacgtt 8

- 121 -

<210> 639
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 639
tcatcgat 8

<210> 640
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 640
taaacggt 8

<210> 641
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 641
ccaacggt 8

<210> 642
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 642
gctcga 6

<210> 643
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 643
cgacgt 6

<210> 644
<211> 6
<212> DNA
<213> Artificial Sequence

<220>

- 122 -

<223> Synthetic Sequence

<400> 644
cgtcgt 6

<210> 645
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 645
acgtgt 6

<210> 646
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 646
cgttcg 6

<210> 647
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 647
gagcaagctg gaccttccat - 20

<210> 648
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 648
cgcgta 6

<210> 649
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 649
cgtacg 6

<210> 650

- 123 -

<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 650
tcaccggt 8

<210> 651
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 651
caagagatgc taacaatgca 20

<210> 652
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 652
acccatcaat agctotgtgc 20

<210> 653
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 653
ccatcgat 8

<210> 654
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 654
tcgacgtc 8

<210> 655
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 655 ctagcgct	8
<210> 656 <211> 8 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 656 taagcgct	8
<210> 657 <211> 13 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 657 tcgcgaattc gcg	13
<210> 658 <211> 19 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 658 atggaaggctc cagcgttct	19
<210> 659 <211> 17 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 659 actggacgtt agcgtga	17
<210> 660 <211> 18 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic Sequence	
<400> 660 cgcctggggc tggctctgg	18
<210> 661 <211> 18	

- 125 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 661
gtgtcggggt ctccgggc 18

<210> 662
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 662
gtgccggggt ctccgggc 18

<210> 663
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 663
cgccgtcgcg gcggttgg 18

<210> 664
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 664
gaagttcacg ttgaggggca t 21

<210> 665
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 665
atctggtgag ggcaagctat g 21

<210> 666
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 126 -

<400> 666	
gttgaaaccc gagaacatca t	21
<210> 667	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 667	
gcaacggtt	8
<210> 668	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 668	
gtaacggtt	8
<210> 669	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 669	
cgaacggtt	8
<210> 670	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 670	
gaaacggtt	8
<210> 671	
<211> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic Sequence	
<400> 671	
caaacggtt	8
<210> 672	
<211> 8	
<212> DNA	

- 127 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 672

ctaacggtt 8

<210> 673

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 673

ggaacggtt 8

<210> 674

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 674

tgaacggtt 8

<210> 675

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 675

acaacggtt 8

<210> 676

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 676

ttaacggtt 8

<210> 677

<211> 8

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 677

- 128 -

aaaacggtt

8

<210> 678
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 678

ataacggtt

8

<210> 679
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 679

aacgtttct

8

<210> 680
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 680

tccgatcg

8

<210> 681
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 681

tccgtacg

8

<210> 682
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 682

gctagacgct agcgtga

17

<210> 683
<211> 25
<212> DNA
<213> Artificial Sequence

- 129 -

<220>
<223> Synthetic Sequence

<400> 683
gagaacgctg gacctcatca tccat 25

<210> 684
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 684
gagaacgcta gaccttctat 20

<210> 685
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 685
actagacgtt agtgtga 17

<210> 686
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 686
cacaccttgg tcaatgtcac gt 22

<210> 687
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 687
tctccatcct atggttttat cg 22

<210> 688
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 688
cgctggacct tccat 15

- 130 -

<210> 689
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 689
caccaccttg gtcaatgtca cgt 23

<210> 690
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 690
gctagacggt agctgga 17

<210> 691
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 691
agtgcgattg cagatcg 17

<210> 692
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 692
ttttcgttt gtggtttgt ggtt 24

<210> 693
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 693
ttttcgtttgc tcgttttgc gtt 23

<210> 694
<211> 24
<212> DNA
<213> Artificial Sequence

- 131 -

<220>
<223> Synthetic Sequence

<400> 694
tttttgtttt gtggttttgt gggt 24

<210> 695
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 695
accgcatgga ttctaggcca 20

<210> 696
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 696
gctagacggt agcgt 15

<210> 697
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 697
aacgtggac cttccat 17

<210> 698
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 698
tcaangtt 8

<210> 699
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 699
ccttcgat 8

<210> 700
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 700
actagacgtt agtgtga 17

<210> 701
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 701
gctagagggtt agcgtga 17

<210> 702
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 702
atggactctc cagcgttctc 20

<210> 703
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 703
atcgactctc gagcgttctc 20

<210> 704
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 704
gctagacgtt agc 13

<210> 705
<211> 9

- 133 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 705
gctagacgt 9

<210> 706
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 706
agtgcgattc gagatcg 17

<210> 707
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<223> Synthetic Sequence

<400> 707
tcagngct 8

<210> 708
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 708
ctgattgctc tctcgtga 18

<210> 709
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<223> Synthetic Sequence

<400> 709
tnaacgtt 8

- 134 -

<210> 710
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 710
gagaangctg gaccttccat 20

<210> 711
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 711
gctagacgtt aggctga 17

<210> 712
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 712
gctacttagc gtga 14

<210> 713
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 713
gctaccttag cgtga 15

<210> 714
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 714
atcgacttcg agcggttctc 19

<210> 715
<211> 20

- 135 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 715
atgcactctg cagcgttctc 20

<210> 716
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 716
agtgactctc cagcgttctc 20

<210> 717
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 717
gccagatggt agctgga 17

<210> 718
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 718
atcgactcga gcgttctc 18

<210> 719
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 719
atcgatcgag cgttctc 17

<210> 720
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)

- 136 -

<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 720
gagaacgctc gaccttcgat 20

<210> 721
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 721
gctagacgtt agctgga 17

<210> 722
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 722
atcgactctc gagcgttctc 20

<210> 723
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 723
tagacgttag cgtga 15

<210> 724
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 724
cgactctcga gcgttctc 18

<210> 725
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 725
ggggtcgacc ttggagggg g 21

<210> 726
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 726
gctaacgtta gcgtga 16

<210> 727
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 727
cgtcgctcgt 9

<210> 728
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (14)...(14)
<223> m5c

<223> Synthetic Sequence

<400> 728
gagaacgctg gacnttccat 20

<210> 729
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (18)...(18)
<223> m5c

<223> Synthetic Sequence

<400> 729
atcgacctac gtgcgttntc 20

<210> 730
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (3)...(3)

- 138 -

<223> m5c

<223> Synthetic Sequence

<400> 730
atngacctac gtgcgttctc 20

<210> 731
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (7)...(7)
<223> m5c

<223> Synthetic Sequence

<400> 731
gctagangtt agcgt 15

<210> 732
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (14)...(14)
<223> m5c

<223> Synthetic Sequence

<400> 732
atcgactctc gagngttctc 20

<210> 733
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 733
ggggtaatgc atcagggggg 20

<210> 734
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 734
ggctgtattc ctgactgccc 20

<210> 735
<211> 17

- 139 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 735
ccatgctaac ctctagc

17

<210> 736
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 736
gctagatgtt agcgtga

17

<210> 737
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 737
cgtaccttac ggtga

15

<210> 738
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 738
tccatgctgg tcctgatgct

20

<210> 739
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 739
atcgactctc tcgagcggtc tc

22

<210> 740
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 740
gctagagctt agcgtga 17

<210> 741
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 741
atcgactctc gagtgttctc 20

<210> 742
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 742
aacgctcgac cttcgat 17

<210> 743
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 743
ctcaacgctg gaccttccat 20

<210> 744
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 744
atcgacctac gtgcgttctc 20

<210> 745
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 745
gagaatgctg gaccttccat 20

<210> 746
<211> 17
<212> DNA

- 141 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 746

tcacgctaac ctctgac

17

<210> 747

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (1)...(3)

<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 747

gagaacgctc cagcactgat

20

<210> 748

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (1)...(3)

<223> Biotin moiety attached at 5' end of sequence.

<223> Synthetic Sequence

<400> 748

gagcaagctg gaccttccat

20

<210> 749

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 749

cgctagaggt tagcgtga

18

<210> 750

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 750

gctagatggt aacgt

15

<210> 751

- 142 -

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 751
atggaaggtc cacgttctc 19

<210> 752
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 752
gctagatggt agcgt 15

<210> 753
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 753
gctagacggt agtgt 15

<210> 754
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 754
tccatgacgg tcctgatgct 20

<210> 755
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 755
tccatggcgg tcctgatgct 20

<210> 756
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 143 -

<400> 756
gctagacgat agcgt 15

<210> 757
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 757
gctagtcgat agcgt 15

<210> 758
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 758
tccatgacgt tcctgatgct 20

<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 759
tccatgtcgt tcctgatgct 20

<210> 760
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (13)...(13)
<223> m5c

<223> Synthetic Sequence

<400> 760
gctagacggt agngt 15

<210> 761
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 761

- 144 -

gctaggcggtt agcgt

15

<210> 762
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 762
tccatgtngg tcctgatgct

20

<210> 763
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (12)...(12)
<223> m5c

<223> Synthetic Sequence

<400> 763
tccatgtcgg tncatgatgct

20

<210> 764
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<221> modified_base
<222> (3)...(3)
<223> m5c

<221> modified_base
<222> (10)...(10)
<223> m5c

<221> modified_base
<222> (14)...(14)
<223> m5c

<400> 764
atngactctn gagngttctc

20

<210> 765
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 145 -

<223> Synthetic Sequence

<400> 765
atggaaggctc cagtgttctc 20

<210> 766
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 766
gcatgacgtt gagct 15

<210> 767
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 767
ggggtcaacg ttgagggggg 20

<210> 768
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 768
ggggtcaagt ctgagggggg 20

<210> 769
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 769
cgcgcgcgcg cgcgcgcgcg 20

<210> 770
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 770
cccccccccc ccccccccc cccccccc 28

<210> 771

- 146 -

<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 771
cccccccccc ccccccccccc ccccccccccc ccccc 35

<210> 772
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 772
tccatgtcgc tcctgatcct 20

<210> 773
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 773
gctaaacggt agcgt 15

<210> 774
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 774
tccatgtcga tcctgatgct 20

<210> 775
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 775
tccatgccgg tcctgatgct 20

<210> 776
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 776
aaaatcaacg ttgaaaaaaa 20

<210> 777
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 777
tccataacgt tcctgatgct 20

<210> 778
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 778
tggaggtccc accgagatcg gag 23

<210> 779
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 779
cgtcgtcgtc gtcgtcgtcg t 21

<210> 780
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 780
ctgctgctgc tgctgctgct g 21

<210> 781
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 781
gagaacgctc cgaccttcga t 21

<210> 782
<211> 15

- 148 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 782
gctagatgtt agcgt 15

<210> 783
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 783
gcatgacgtt gagct 15

<210> 784
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 784
tcaatgctga 10

<210> 785
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 785
tcaacgttga 10

<210> 786
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

- 149 -

<400> 786
tcaacgttga 10

<210> 787
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 787
gcaatattgc 10

<210> 788
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (8)...(10)
<223> Conjugated to FITC moiety.

<223> Synthetic Sequence

<400> 788
gcaatattgc 10

<210> 789
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 789
agttgcaact 10

<210> 790
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 790
tcttcgaa 8

<210> 791
<211> 8
<212> DNA
<213> Artificial Sequence

- 150 -

<220>
<223> Synthetic Sequence

<400> 791
tcaacgtc 8

<210> 792
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 792
ccatgtcggg cctgatgct 19

<210> 793
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 793
gtttttatat aatttggg 18

<210> 794
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 794
tttttggttg tcgttttggtc gtt 23

<210> 795
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 795
ttggggggggg tt 12

<210> 796
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 796
gggggttgggg gtt 13

- 151 -

<210> 797
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 797
ggtggtgtag gttttgg 17

<210> 798
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 798
gagaangctc gaccttcgat 20

<210> 799
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 799
tcaacgttaa cgttaacgtt 20

<210> 800
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (8)...(8)
<223> m5c

<223> Synthetic Sequence

<400> 800
gagcaagntg gaccttccat 20

<210> 801

- 152 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 801
gagaangctc cagcactgat 20

<210> 802
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (5)...(5)
<223> m5c

<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 802
tcaangttga 10

<210> 803
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (2)...(2)
<223> m5c

<221> misc_feature
<222> (8)...(10)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 803
gnaatattgc 10

<210> 804
<211> 24
<212> DNA
<213> Artificial Sequence

- 153 -

<220>
<223> Synthetic Sequence

<400> 804
tgctgctttt gtcgttttgt gctt 24

<210> 805
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 805
ctgcgttagc aatttaactg tg 22

<210> 806
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 806
tccatgacgt tcctgatgct 20

<210> 807
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 807
tgcatgccgt gcatccgtac acagctct 28

<210> 808
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 808
tgcatgccgt acacagctct 20

<210> 809
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 809
tgcatcagct ct 12

- 154 -

<210> 810
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 810
tgcgctct 8

<210> 811
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 811
cccccccccc ccccccccccc 20

<210> 812
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 812
cccccccccc cc 12

<210> 813
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 813
cccccccc 8

<210> 814
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 814
tgcacgagct ct 12

<210> 815
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 155 -

<223> Synthetic Sequence

<400> 815
tgcatgccgt acacagctct 20

<210> 816
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 816
gagcaagctg gaccttccat 20

<210> 817
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 817
tcaacgttaa cgtaaagtt aacgttaacg tt 32

<210> 818
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 818
gagaacgctc gaccttcgat 20

<210> 819
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 819
gtccccattt cccagaggag gaaat 25

<210> 820
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 820
ctagcggctg acgtcatcaa gctag 25

<210> 821

- 156 -

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 821
ctagcttgat gacgtcagcc gctag 25

<210> 822
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 822
cggctgacgt catcaa 16

<210> 823
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 823
ctgacgtg 8

<210> 824
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 824
ctgacgtcat 10

<210> 825
<211> 21
<212> DNA^t
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 825
attcgatcgg ggcggggcga g 21

<210> 826
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 157 -

<400> 826
ctcgccccgc cccgatcgaa t 21

<210> 827
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 827
gactgacgtc agcgt 15

<210> 828
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 828
ctagcggctg acgtcataaa gctagc 26

<210> 829
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 829
ctagctttat gacgtcagcc gctagc 26

<210> 830
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 830
ctagcggctg agctcataaa gctagc 26

<210> 831
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 831
ctagtggctg acgtcatcaa gctag 25

<210> 832
<211> 20

- 158 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 832
tccaccacgt ggtctatgct 20

<210> 833
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 833
gggaatgaaa gattttatta taag 24

<210> 834
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 834
tctaaaaacc atctattctt aaccct 26

<210> 835
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 835
agctcaacgt catgc 15

<210> 836
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 836
ttaacggtgg tagcggtatt ggtc 24

<210> 837
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 159 -

<400> 837
ttaagaccaa taccgctacc accg 24
<210> 838
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 838
gatctagtga tgagtcagcc ggatc 25
<210> 839
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 839
gatccggctg actcatcact agatc 25
<210> 840
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 840
tccaagacgt tcctgatgct 20
<210> 841
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 841
tccatgacgt ccctgatgct 20
<210> 842
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic Sequence
<400> 842
tccaccacgt ggctgatgct 20
<210> 843
<211> 17
<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 843

ccacgtggac ctctagc 17

<210> 844

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 844

tcagaccacg tggtcgggtg ttcctga 27

<210> 845

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 845

tcaggaacac ccgaccacgt ggtctga 27

<210> 846

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 846

catttccacg atttccca 18

<210> 847

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 847

ttcctctctg caagagact 19

<210> 848

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 848

- 161 -

tgtatctctc tgaaggact

19

<210> 849
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 849
ataaagcgaa actagcagca gtttc

25

<210> 850
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 850
gaaactgctg ctagtttcgc tttat

25

<210> 851
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 851
tgcccaaaga ggaaaatttg tttcatacag

30

<210> 852
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 852
ctgtatgaaa caaattttcc tctttgggca

30

<210> 853
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 853
ttagggtag ggtaggggtt

20

<210> 854
<211> 20
<212> DNA
<213> Artificial Sequence

- 162 -

<220>
<223> Synthetic Sequence

<400> 854
tccatgagct tctgatgct 20

<210> 855
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 855
aaaacatgac gttcaaaaaa 20

<210> 856
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 856
aaaacatgac gttcgggggg 20

<210> 857
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 857
ggggcatgag cttcgggggg 20

<210> 858
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 858
ctaggctgac gtcacaaagc tagt 24

<210> 859
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 859
tctgacgtca tctgacgttg gctgacgtct 30

- 163 -

<210> 860
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 860
ggaattagta atagatatag aagtt 25

<210> 861
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 861
tttacctttt ataaacataa ctaaaacaaa 30

<210> 862
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 862
gcgttttttt ttgcg 15

<210> 863
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 863
atatctaadc aaaacattaa caaa 24

<210> 864
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 864
tctatcccag gtggttcctg ttag 24

<210> 865
<211> 20
<212> DNA
<213> Artificial Sequence

- 164 -

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 865
tccatgacgt tcctgatgct 20

<210> 866
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (1)...(3)
<223> Conjugated to biotin moiety.

<223> Synthetic Sequence

<400> 866
tccatgagct tcctgatgct 20

<210> 867
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (11)...(13)
<223> Conjugated to FITC moiety.

<221> misc_feature
<222> (0)...(0)
<223> Has phosphodiester backbone.

<223> Synthetic Sequence

<400> 867
tttttttttt ttt 13

<210> 868
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (11)...(13)
<223> Conjugated to biotin moiety.

<221> misc_feature
<222> (0)...(0)
<223> Has phosphorothioate and phosphodiester chimeric
backbone with phosphodiester on 3' end.

<223> Synthetic Sequence

<400> 868
tttttttttt ttt 13

<210> 869
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 869
ctagcttgat gagctcagcc gctag 25

<210> 870
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 870
ttcagttgtc ttgctgctta gctaa 25

<210> 871
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 871
tccatgagct tcctgagtct 20

<210> 872
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 872
ctagcggctg acgtcatcaa tctag 25

<210> 873
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 873
tgctagctgt gcctgtacct 20

<210> 874
<211> 23
<212> DNA

- 166 -

<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 874
atgctaaagg acgtcacatt gca 23

<210> 875
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 875
tgcaatgtga cgtccttttag cat 23

<210> 876
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 876
gtaggggact ttccgagctc gagatcctat g 31

<210> 877
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 877
cataggatct cgagctcgga aagtccccta c 31

<210> 878
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 878
ctgtcaggaa ctgcaggtaa gg 22

<210> 879
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 879

- 167 -

cataacatag gaatattttac tcctcgc

27

<210> 880
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 880

ctccagctcc aagaaaggac g

21

<210> 881
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 881

gaagtttctg gtaagtcttc g

21

<210> 882
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 882

tgctgctttt gtgcttttgt gctt

24

<210> 883
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 883

tcgtcgtttt gtggttttgt gggt

24

<210> 884
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 884

tcgtcgtttt tcgttttgtc gtt

23

<210> 885
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 885
tcctgacgtt cggcgcgcgc cc 22

<210> 886
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 886
tgctgctttt gtgcttttgt gctt 24

<210> 887
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 887
tccatgagct tcctgagctt 20

<210> 888
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 888
tcgtcgtttc gtcgttttga cggt 24

<210> 889
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 889
tcgtcgtttg cgtgcgtttc gtcgtt 26

<210> 890
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 890
tcgcgtgcgt tttgtcgttt tgacgtt 27

- 169 -

<210> 891
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 891
ttcgtcgttt tgtcgttttg tcggt 25

<210> 892
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 892
tcctgacggg gaagt 15

<210> 893
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 893
tcctggcgtg gaagt 15

<210> 894
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 894
tcctggcggg gaagt 15

<210> 895
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 895
tcctggcggt gaagt 15

<210> 896
<211> 15
<212> DNA
<213> Artificial Sequence

- 170 -

<220>
<223> Synthetic Sequence

<400> 896
tcctgacgtg gaagt 15

<210> 897
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 897
gcgacggttcg gcgcgcgccc 20

<210> 898
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 898
gcgacgggacg gcgcgcgccc 20

<210> 899
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 899
gcggcgtgacg gcgcgcgccc 20

<210> 900
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 900
gcggcgggtcg gcgcgcgccc 20

<210> 901
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 901
gcgacgggtcg gcgcgcgccc 20

- 171 -

<210> 902
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 902
gcggcggttcg gcgcgcgccc 20

<210> 903
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 903
gcgacgtgcg gcgcgcgccc 20

<210> 904
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 904
tcgtcgctgt ctccg 15

<210> 905
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 905
tgtgggggtt ttggttttgg 20

<210> 906
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 906
aggggagggg aggggagggg 20

<210> 907
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

- 172 -

<223> Synthetic Sequence

<400> 907
tgtgtgtgtg tgtgtgtgtg t 21

<210> 908
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 908
ctctctctct ctctctctct ct 22

<210> 909
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 909
ggggtcgacg tcgagggggg 20

<210> 910
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 910
atatatatat atatatatat at 22

<210> 911
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 911
tttttttttt tttttttttt ttttttt 27

<210> 912
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 912
tttttttttt tttttttttt t 21

<210> 913

- 173 -

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 913
tttttttttt tttttttt 18

<210> 914
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 914
gctagagggg aggggt 15

<210> 915
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 915
gctagatgtt agggg 15

<210> 916
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 916
gcatgagggg gagct 15

<210> 917
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 917
atggaaggct cagggggctc 20

<210> 918
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 174 -

<400> 918
atggactctg gagggggctc 20

<210> 919
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 919
atggaaggtc caaggggctc 20

<210> 920
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 920
gagaaggggg gaccttgat 20

<210> 921
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 921
gagaaggggg gaccttccat 20

<210> 922
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 922
gagaaggggc cagcactgat 20

<210> 923
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 923
tccatgtggg gcctgatgct 20

<210> 924
<211> 20

- 175 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 924
tccatgaggg gcctgatgct 20

<210> 925
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 925
tccatgtggg gcctgctgat 20

<210> 926
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 926
atggactctc cggggttctc 20

<210> 927
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 927
atggaaggtc cggggttctc 20

<210> 928
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 928
atggactctg gaggggtctc 20

<210> 929
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 176 -

<400> 929
atggaggctc catggggctc 20

<210> 930
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 930
atggactctg gggggttctc 20

<210> 931
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 931
tccatgtggg tggggatgct 20

<210> 932
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 932
tccatgcggg tggggatgct 20

<210> 933
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 933
tccatggggg tcctgatgct 20

<210> 934
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 934
tccatggggt ccctgatgct 20

<210> 935
<211> 20
<212> DNA

- 177 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 935
tccatgggggt gcctgatgct 20

<210> 936
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 936
tccatgggggt tcctgatgct 20

<210> 937
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 937
tccatcgggg gcctgatgct 20

<210> 938
<211> 14
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 938
gctagagggga gtgt 14

<210> 939
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 939
tttttttttt tttttttt 18

<210> 940
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<221> misc_difference
<222> (2)...(2)
<223> m is a or c

- 178 -

<221> misc_difference
<222> (18)...(18)
<223> m i s a o r c

<223> Synthetic Sequence

<400> 940
gmgggtcaacg ttgagggm gg 21

<210> 941
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 941
ggggagttcg ttgagggggg g 21

<210> 942
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 942
tcgtcgtttc cccccccccc 20

<210> 943
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 943
ttgggggggtt tttttttttt ttttt 25

<210> 944
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 944
tttaaatttt aaaatttaaa ata 23

<210> 945
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 179 -

<400> 945
ttgggtttttt tgggtttttt ttgg 24

<210> 946
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 946
tttccctttt ccccttttcc cctc 24

<210> 947
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_difference
<222> (21)...(21)
<223> s is g or c

<223> Synthetic Sequence

<400> 947
gggggtcatcg atgagggggg s 21

<210> 948
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 948
tccatgacgt tcctgacgtt 20

<210> 949
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 949
tccatgacgt tcctgacgtt 20

<210> 950
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 950

- 180 -

tccatgacgt tcctgacgtt

20

<210> 951
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 951

tccatgacgt tcctgacgtt

20

<210> 952
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 952

tccatgacgt tcctgacgtt

20

<210> 953
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 953

tccatgacgt tcctgacgtt

20

<210> 954
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 954

tccatgacgt tcctgacgtt

20

<210> 955
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 955

tccatgacgt tcctgacgtt

20

<210> 956
<211> 20
<212> DNA
<213> Artificial Sequence

- 181 -

<220>
<223> Synthetic Sequence

<400> 956
tccatgacgt tcctgacgtt 20

<210> 957
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 957
tccatgacgt tcctgacgtt 20

<210> 958
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 958
tccatgacgt tcctgacgtt 20

<210> 959
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 959
gggggacgat cgtcggggg 19

<210> 960
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 960
ggggggtcgta cgacgggggg 20

<210> 961
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 961
tttttttttt tttttttttt tttt 24

- 182 -

<210> 962
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 962
aaaaaaaaaa aaaaaaaaaa aaaa 24

<210> 963
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 963
cccccccccc ccccccccc cccc 24

<210> 964
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 964
tcgtcgtttt gtcgttttgt cggt 24

<210> 965
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 965
tcgtcgtttt gtcgttttgt cggt 24

<210> 966
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 966
tcgtcgtttt gtcgttttgt cggt 24

<210> 967
<211> 24
<212> DNA
<213> Artificial Sequence

- 183 -

<220>
<223> Synthetic Sequence

<400> 967
tcgtcgtttt gtcgttttgt cggt 24

<210> 968
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 968
ggggtcaacg ttgagggggg 20

<210> 969
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 969
ggggtcaacg ttgagggggg 20

<210> 970
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 970
ggggtcaagc ttgagggggg 20

<210> 971
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 971
tgctgcttcc cccccccccc 20

<210> 972
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 972
ggggacgtcg acgtgggggg 20

- 184 -

<210> 973
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 973
ggggtcgtcg acgagggggg 20

<210> 974
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 974
ggggtcgacg tacgtcgagg gggg 24

<210> 975
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 975
ggggaccggt accggtgggg gg 22

<210> 976
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 976
gggtcgacgt cgagggggg 19

<210> 977
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 977
ggggtcgacg tcgaggggg 19

<210> 978
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

- 185 -

<223> Synthetic Sequence

<400> 978
ggggaacggtt aacgttgggg gg 22

<210> 979
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 979
ggggtcaccg gtgagggggg 20

<210> 980
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 980
ggggtcggttc gaacgagggg gg 22

<210> 981
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 981
ggggacgttc gaacgtgggg gg 22

<210> 982
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 982
tcaactttga 10

<210> 983
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 983
tcaagcttga 10

<210> 984

- 186 -

<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 984
tcacgatcgt ga 12

<210> 985
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 985
tcagcatgct ga 12

<210> 986
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 986
gggggagcat gctggggggg 20

<210> 987
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 987
gggggggggg gggggggggg 20

<210> 988
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 988
gggggacgat atcgtcgggg gg 22

<210> 989
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 187 -

<400> 989
gggggacgac gtcgtcgggg gg 22

<210> 990
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 990
gggggacgag ctcgtcgggg gg 22

<210> 991
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 991
gggggacgta cgtcgggggg 20

<210> 992
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 992
tcaacgtt 8

<210> 993
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 993
tccataccgg tcctgatgct 20

<210> 994
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 994
tccataccgg tcctaccggt 20

<210> 995
<211> 20

- 188 -

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 995
gggggacgat cggtgggggg 20

<210> 996
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 996
ggggaacgat cgtcgggggg 20

<210> 997
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 997
ggggggacga tcgtcggggg g 21

<210> 998
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 998
gggggacgat cgtcgggggg g 21

<210> 999
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 999
aaagacgtta aa 12

<210> 1000
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

- 189 -

<400> 1000
aaagagctta aa 12

<210> 1001
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (6)...(6)
<223> m5c

<223> Synthetic Sequence

<400> 1001
aaagangtta aa 12

<210> 1002
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1002
aaattcggaa aa 12

<210> 1003
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1003
gggggtcatc gatgaggggg g 21

<210> 1004
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1004
gggggtcaac gttgaggggg g 21

<210> 1005
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1005
atgtagctta ataacaaagc 20

- 190 -

<210> 1006
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1006
ggatcccttg agttacttct 20

<210> 1007
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1007
ccattccact tctgattacc 20

<210> 1008
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1008
tatgtattat catgtagata 20

<210> 1009
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1009
agcctacgta ttcaccctcc 20

<210> 1010
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1010
ttcctgcaac tactattgta 20

<210> 1011
<211> 20
<212> DNA
<213> Artificial Sequence

- 191 -

<220>
<223> Synthetic Sequence

<400> 1011
atagaaggcc ctacaccagt 20

<210> 1012
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1012
ttacaccggt ctatggaggt 20

<210> 1013
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1013
ctaaccagat caagtctagg 20

<210> 1014
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1014
cctagacttg atctggttag 20

<210> 1015
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1015
tataagcctc gtccgacatg 20

<210> 1016
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1016
catgtcggac gaggcttata 20

- 192 -

<210> 1017
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1017
tggtggtggg gagtaagctc 20

<210> 1018
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1018
gagctactcc cccaccacca 20

<210> 1019
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1019
gccttcgatac ttcggttgga 20

<210> 1020
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1020
tggacttctc tttgccgtct 20

<210> 1021
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1021
atgctgtagc ccagcgataa 20

<210> 1022
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 193 -

<223> Synthetic Sequence

<400> 1022
accgaatcag cggaagtgga 20

<210> 1023
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1023
tccatgacgt tcctgacgtt 20

<210> 1024
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1024
ggagaaaccc atgagctcat ctgg 24

<210> 1025
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1025
accacagacc agcaggcaga 20

<210> 1026
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1026
gagcgtgaac tgcgcgaaga 20

<210> 1027
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1027
tcggtaccct tgcagcggtt 20

<210> 1028

- 194 -

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1028
ctggagccct agccaaggat 20

<210> 1029
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1029
gcgactccat caccagcgat 20

<210> 1030
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1030
cctgaagtaa gaaccagatg t 21

<210> 1031
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1031
ctgtgttatc tgacatacac c 21

<210> 1032
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1032
aattagcctt aggtgattgg g 21

<210> 1033
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1033
acatctgggtt cttacttcag g 21

<210> 1034
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1034
ataagtcata ttttgggaac tac 23

<210> 1035
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1035
cccaatcacc taaggcta t 21

<210> 1036
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1036
ggggtcgtcg acgagggggg 20

<210> 1037
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1037
ggggtcgttc gaacgagggg gg 22

<210> 1038
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1038
ggggacgttc gaacgtgggg gg 22

<210> 1039
<211> 15

- 196 -

<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (9)...(9)
<223> n is 5-methylcytosine.

<223> Synthetic Sequence

<400> 1039
tcctggcgng gaagt 15

<210> 1040
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1040
ggggaacgac gtcgttgggg gg 22

<210> 1041
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1041
ggggaacgta cgtcgggggg 20

<210> 1042
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1042
ggggaacgta cgtacgttgg gggg 24

<210> 1043
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1043
ggggtcaccg gtgagggggg 20

<210> 1044
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1044
ggggtcgacg tacgtcgagg gggg 24

<210> 1045
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1045
ggggaccggt accggtgggg gg 22

<210> 1046
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1046
gggtcgacgt cgagggggg 19

<210> 1047
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1047
ggggtcgacg tcgagggg 18

<210> 1048
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1048
ggggaacgtt aacgttgggg gg 22

<210> 1049
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1049
ggggacgtcg acgtggggg 19

- 198 -

<210> 1050
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1050
gcactcttcg aagctacagc cggcagcctc tgat 34

<210> 1051
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1051
cggctcttcc atgaggtctt tgctaatttt gg 32

<210> 1052
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1052
cggctcttcc atgaaagtct ttggacgatg tgagc 35

<210> 1053
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1053
tcctgcaggt taagt 15

<210> 1054
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1054
gggggtcgtt cgttgggggg 20

<210> 1055
<211> 20
<212> DNA
<213> Artificial Sequence

- 199 -

<220>
<223> Synthetic Sequence

<400> 1055
gggggatgat tgggtggggg 20

<210> 1056
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<221> modified_base
<222> (11)...(11)
<223> m5c

<223> Synthetic Sequence

<400> 1056
gggggangat nggtggggg 20

<210> 1057
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1057
gggggagcta gcttggggg 20

<210> 1058
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1058
ggttcttttg gtccttgtct 20

<210> 1059
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1059
ggttcttttg gtcctcgtct 20

<210> 1060
<211> 20
<212> DNA

- 200 -

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1060

ggttcttttg gtccttatct

20

<210> 1061

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1061

ggttcttggt ttccttgtct

20

<210> 1062

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1062

tggtcttttg gtccttgtct

20

<210> 1063

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1063

ggttcaaag gtccttgtct

20

<210> 1064

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1064

gggtcttttg ggccttgtct

20

<210> 1065

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1065

- 201 -

tccaggactt ctctcagggtt tttt

24

<210> 1066
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1066
tccaaaactt ctctcaaatt

20

<210> 1067
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1067
tactactttt atacttttat actt

24

<210> 1068
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1068
tgtgtgtgtg tgtgtgtgtg tgtg

24

<210> 1069
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1069
ttgttggttg tgtttggttg tggtg

25

<210> 1070
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1070
ggctccgggg aggaatttt tgtctat

27

<210> 1071
<211> 19
<212> DNA
<213> Artificial Sequence

- 202 -

<220>
<223> Synthetic Sequence

<400> 1071
gggacgatcg tcggggggg 19

<210> 1072
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1072
gggtcgtcga cgagggggg 20

<210> 1073
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1073
ggtcgtcgac gagggggg 19

<210> 1074
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1074
gggtcgtcgt cgtgggggg 20

<210> 1075
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1075
ggggacgatc gtcgggggg 20

<210> 1076
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1076
ggggacgtcg tcgtggggg 20

- 203 -

<210> 1077
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1077
ggggtcgacg tcgacgtcga gggggggg 27

<210> 1078
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1078
ggggaaccgc ggttgggggg g 21

<210> 1079
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1079
ggggacgacg tcgtgggggg g 21

<210> 1080
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1080
tcgtcgtcgt cgtcgtgggg ggg 23

<210> 1081
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1081
tcctgccggg gaagt 15

<210> 1082
<211> 15
<212> DNA
<213> Artificial Sequence

- 204 -

<220>
<223> Synthetic Sequence

<400> 1082
tcctgcaggg gaagt 15

<210> 1083
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1083
tcctgaaggg gaagt 15

<210> 1084
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1084
tcctggcggg caagt 15

<210> 1085
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1085
tcctggcggg taagt 15

<210> 1086
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1086
tcctggcggg aaagt 15

<210> 1087
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1087
tccgggcggg gaagt 15

- 205 -

<210> 1088
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1088
tcggggcggg gaagt 15

<210> 1089
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1089
tcccgggcggg gaagt 15

<210> 1090
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1090
gggggacgtt ggggg 15

<210> 1091
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1091
ggggtttttt ttttggggg 20

<210> 1092
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Sequence

<400> 1092
ggggccccc ccccgggggg 20

<210> 1093
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

WO 02/053141

PCT/US01/48458

- 206 -

<223> Synthetic Sequence

<400> 1093

ggggttgttg ttgttggggg g

21

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.